Skip to main content
eLife logoLink to eLife
. 2023 Jan 10;12:e85837. doi: 10.7554/eLife.85837

Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers

Shenjie Wu 1, Nancy C Hernandez Villegas 2, Daniel W Sirkis 3, Iona Thomas-Wright 4, Richard Wade-Martins 4, Randy Schekman 1,
Editors: Suzanne R Pfeffer5, Suzanne R Pfeffer6
PMCID: PMC9876576  PMID: 36626307

Abstract

Alpha-synuclein (α-syn), a major component of Lewy bodies found in Parkinson’s disease (PD) patients, has been found exported outside of cells and may mediate its toxicity via cell-to-cell transmission. Here, we reconstituted soluble, monomeric α-syn secretion by the expression of DnaJ homolog subfamily C member 5 (DNAJC5) in HEK293T cells. DNAJC5 undergoes palmitoylation and anchors on the membrane. Palmitoylation is essential for DNAJC5-induced α-syn secretion, and the secretion is not limited by substrate size or unfolding. Cytosolic α-syn is actively translocated and sequestered in an endosomal membrane compartment in a DNAJC5-dependent manner. Reduction of α-syn secretion caused by a palmitoylation-deficient mutation in DNAJC5 can be reversed by a membrane-targeting peptide fusion-induced oligomerization of DNAJC5. The secretion of endogenous α-syn mediated by DNAJC5 is also found in a human neuroblastoma cell line, SH-SY5Y, differentiated into neurons in the presence of retinoic acid, and in human-induced pluripotent stem cell-derived midbrain dopamine neurons. We propose that DNAJC5 forms a palmitoylated oligomer to accommodate and export α-syn.

Research organism: Human

Introduction

Parkinson’s disease (PD), the second most common neurodegenerative disease, is characterized by the deposit of clumps of protein aggregate, lipid and damaged organelles known as Lewy bodies (LBs) (Dauer and Przedborski, 2003; Shahmoradian et al., 2019). One of the main constituents of LB is the presynaptic protein alpha-synuclein (α-syn) (Stefanis, 2012). α-syn is encoded by the SNCA gene and is highly abundant in neurons. As a small, intrinsically disordered protein-containing 140 amino acids (AAs), α-syn can be divided into three domains, an amphipathic N-terminal domain where most PD-related mutations are located, including A30P, E46K, and A53T, a central hydrophobic region known as the non-amyloid-β component (NAC) which is essential for aggregation, and an acidic C-terminal domain (Figure 1A; Alderson and Markley, 2013). α-syn can undergo a conformational change from a disordered monomer to an oligomer (Burré et al., 2014; Lashuel et al., 2002), which can further polymerize to form insoluble fibrils (Guerrero-Ferreira et al., 2019; Guerrero-Ferreira et al., 2018; Strohäker et al., 2019).

Figure 1. Reconstitution of α-syn secretion regulated by palmitoylated DNAJC5 in HEK293T cells.

(A) Schematic diagrams of α-syn and DNAJC5. Domains are highlighted in different colors. Red arrows indicate known disease-causing mutations on each protein. (B) Membrane and cytosol fractionation scheme. Briefly, homogenized HEK293T cells were centrifuged at low speed to prepare a post-nuclear supernatant (PNS). High-speed centrifugation was then performed to separate the sedimentable membrane (M) from cytosol (C). (C) Partition of palmitoylated DNAJC5 (P-DNAJC5) and non-palmitoylated DNAJC5 (NP-DNAJC5) between the membrane (M) and cytosol (C) fractions. DNAJC5 was immunoprecipitated from cytosol and membrane with anti-FLAG resin and evaluated by Coomassie-blue stained SDS-PAGE. (D) α-syn secretion 16 h after transfection. The secretion of P-DNAJC5 in the medium was detected. (E) α-syn secretion 36 h after transfection. NP-DNAJC5 was also secreted in the medium together with α-syn.

Figure 1—source data 1. Uncropped immunoblot and gel images corresponding to Figure 1.

Figure 1.

Figure 1—figure supplement 1. Validation of palmitoylation of DNAJC5 in various cell lines.

Figure 1—figure supplement 1.

(A) Membrane and cytosol fractionation of various cell lines (HEK293T, MDA-MB-231, and Hela) transfected with DNAJC5. The fractionation was performed as depicted in Figure 1B. C, cytosol; M, membrane; PNS, post-nuclear supernatant. Transferrin receptor (TFR) was used as a membrane marker. Tubulin was used as a cytosol marker. (B) In vitro depalmitoylation assay. Sedimented membranes (M) from different DNAJC5-transfected cell lines were collected and resuspended in 0.25 M Tris pH 7.2 buffer or 0.25 M Hydroxylamine (HA) pH 7.2 buffer. After overnight incubation at room temperature, the samples were examined by SDS-PAGE followed by anti-DNAJC5 immunoblot. PNS and C were used to compare the mobility of P-DNAJC5 and NP-DNAJC5, respectively.
Figure 1—figure supplement 1—source data 1. Uncropped immunoblot images corresponding to Figure 1—figure supplement 1.

Figure 1—figure supplement 2. Secretion of α-syn variants.

Figure 1—figure supplement 2.

(A) Trypan blue cell vital staining after transfection with various constructs used in Figure 1. Ratios of trypan blue positive cells indicate the toxicity caused by transfection. Error bars represent standard deviations of three samples. (B) Secretion of α-syn variants into conditioned medium. Medium was collected, concentrated, and evaluated by SDS-PAGE and immunoblot. (C) Expression of α-syn variants in HEK293T cells. HEK293T cells were co-transfected with Parkinson’s disease (PD)-causing α-syn mutant (A30P, E46K, and A53T) and DNAJC5. (D) Quantification of normalized secretion (amount in medium divided by amount in lysate) of various α-syn variants and DNAJC5. The quantification was based on immunoblot in (B) and (C).
Figure 1—figure supplement 2—source data 1. Uncropped immunoblot images corresponding to Figure 1—figure supplement 2.

Figure 1—figure supplement 3. Secretion of α-syn is partially dependent on endogenous DNAJC5 in HEK293T cells.

Figure 1—figure supplement 3.

(A) Schematic diagram of nanoluciferase (Nluc)-fused α-syn. (B) Nluc-α-syn secretion was stimulated by DNAJC5 expression. Plasmids encoding Nluc-α-syn and DNAJC5 were co-transfected into HEK293T cells. Expression and secretion of proteins were detected with immunoblot 36 hr after transfection. (C) Time-dependent of accumulation of Nluc-α-syn in the medium without DNAJC5 overexpression. After transfecting HEK293T cells with Nluc-α-syn alone, fractions of medium were collected at indicated time points. (D) Chemical structure of quercetin (QLT), a reported DNAJC5 inhibitor. (E) QLT inhibited endogenous Nluc-α-syn secretion in a concentration-dependent manner. AU, arbitrary unit. Secretion assay similar to (B) was performed with treatment of indicated concentration of QLT. Amounts of secreted proteins were quantified with nanoluciferase assay 36 hr after transfection. Immunoblot of α-syn and DNAJC5 in cell lysate after QLT treatment was shown on the right. Error bars represent standard deviations of three samples. (F) Validation of DNAJC5 knockout (KO) cell line generated by CRISPR. Wildtype (WT) HEK293T cell was used as a control. In all three single clones of DNAJC5 KO cell lines, DNAJC5 was not detectable by immunoblot. (G) Treatment of bafilomycin A1 (BaFA1) induced LC3 lipidation in cells. After 24 hr of 100 nM BaFA1 treatment, media were collected, and cells were lysed for evaluation with SDS-PAGE followed by immunoblot. The accumulation of the lipidated form of LC3 (LC3-II) was used to indicate the inhibition of autophagy and lysosomal degradation in cells. (H) Quantification of α-syn secretion from WT and DNAJC5 KO HEK293T cells after 24 hr treatment of BaFA1. The normalized secretion was calculated as nanoluciferase reading from media divided by the reading from cell lysate. Error bars represent standard deviations of three samples.
Figure 1—figure supplement 3—source data 1. Uncropped immunoblot images corresponding to Figure 1—figure supplement 3.

In recent years, studies have suggested that α-syn deposits are not static, but rather actively spread during disease progression. Grafted neurons in PD patients developed α-syn positive LBs years after surgery, suggesting host-to-graft pathology propagation (Kordower et al., 2008; Li et al., 2008). Based on analysis of human pathology, the Braak hypothesis posits that α-syn aggregates can spread in a stereotyped manner from the gastrointestinal tract to the brain, causing neuron loss beginning in the brainstem, extending to the midbrain, and finally to the cortex (Braak et al., 2006; Braak et al., 2003). In more recent work, Braak-like transmission of in vitro generated α-syn fibrils has been recapitulated in mice and non-human primates (Chu et al., 2019; Chung et al., 2020; Kim et al., 2019; Luk et al., 2012).

Less-well understood is the molecular and cellular basis for the transfer of α-syn between cells. Several mechanisms have been proposed for both monomeric and aggregated α-syn export and transfer, including unconventional exocytosis (Jang et al., 2010; Lee et al., 2005), exosomes (Danzer et al., 2012; Emmanouilidou et al., 2010; Stykel et al., 2021), and membrane nanotubes (Abounit et al., 2016; Scheiblich et al., 2021). The extracellular existence of both monomeric and oligomeric α-syn was confirmed in blood and cerebrospinal fluid (CSF) (Borghi et al., 2000; El-Agnaf et al., 2003). Packaging of different conformational forms of α-syn inside extracellular vesicles (EVs) has been reported but requires further vigorous scrutiny to differentiate membrane vesicles from secreted sedimentable aggregates (Brahic et al., 2016).

DNAJC5, also known as cysteine string protein α (CSPα), is a co-chaperone of HSC70 and has been shown to control the extracellular release of many neurodegenerative disease proteins (Fontaine et al., 2016). This process of unconventional traffic has been termed misfolding-associated protein secretion (MAPS) (Fontaine et al., 2016; Lee et al., 2016) as opposed to conventional secretion initiated by an amino-terminal signal peptide required for secretory and membrane protein translocation into the endoplasmic reticulum (Zhang and Schekman, 2013). DNAJC5 contains three domains—a common N-terminal J-domain conserved among DnaJ proteins, the cysteine-string (CS) central domain which is heavily palmitoylated and anchors the protein to late endosomes, and an overall disordered C-terminal domain (Figure 1A). Deletion of DNAJC5 in Drosophila and mice leads to a neurodegenerative phenotype and premature death, indicating that DNAJC5 plays a neuroprotective role in the brain (Zinsmaier, 2010). Transgenic expression of α-syn appears to rescue the neurodegeneration seen on depletion of DNAJC5 (Chandra et al., 2005). A previous study also reported that neuron-derived EVs contain DNAJC5 (Deng et al., 2017). However, the mechanism by which DNAJC5 recognizes and translocates soluble α-syn into a membrane compartment for secretion remains elusive.

In this study, we characterized the mechanism of DNAJC5-induced α-syn secretion in a cell-based secretion assay. Using biochemical characterization and imaging of internalized α-syn in enlarged endosomes as a secretory intermediate, we found previously underappreciated roles of palmitoylation and oligomerization of DNAJC5 in the regulation of α-syn secretion.

Results

Reconstitution of DNAJC5-induced α-syn secretion

Previous studies have shown that α-syn secretion can be stimulated by overexpressing DNAJC5 (Fontaine et al., 2016). The CS domain of DNAJC5 plays a role in promoting stable membrane attachment based on its overall hydrophobicity and by enabling post-translational palmitoylation catalyzed by membrane-bound Asp-His-His-Cys (DHHC) family palmitoyltransferases (Greaves and Chamberlain, 2006). Using a common human cell line, HEK293T, we first tested the expression and subcellular localization of DNAJC5 (Figure 1B). Further subcellular enrichment of DNAJC5 was characterized using a C-terminal FLAG tag. Coomassie blue staining revealed two bands of low and high mobility on SDS-PAGE in the membrane and cytosolic fractions, respectively (Figure 1C). Similar migration profiles of pamitoylated (P-) and non-palmitoylated (NP-) DNAJC5 have been reported (Greaves et al., 2012). We also transfected and fractionated DNAJC5 in other common cell lines including MDA-MB-231 and Hela cells. Compared to DNAJC5 in HEK293T cells, DNAJC5 in MDA-MB-231 and Hela cells appeared predominantly to be in a palmitoylated and membrane-associated form (Figure 1—figure supplement 1A). The mobility of P-DNAJC5 in the membrane fraction shifted to that of NP-DNAJC5 after an overnight depalmitoylation reaction with hydroxylamine (HA) (Figure 1—figure supplement 1B). Thus, we confirm that membrane anchoring of DNAJC5 requires palmitoylation in our assay.

We next coexpressed DNAJC5 together with α-syn to examine their secretion over time. At 16 hour (h) after transfection, we detected similar basal-levels secretion of α-syn in both DNAJC5-negative and -positive conditions. Two bands of DNAJC5 corresponding to P-DNAJC5 and NP-DNAJC5 were seen in the lysate, but only the P-DNAJC5 was secreted into the medium (Figure 1D). The stimulation of α-syn secretion by DNAJC5 became obvious at a longer incubation time (36 h), and at this time point NP-DNAJC5 was also enriched in the medium (Figure 1E). The release of α-syn was not caused by cell death as little to undetected levels of cytoplasmic tubulin found in the culture medium fraction (Figure 1D and E). Cell viability was not affected by transfection of different constructs, as shown by trypan blue staining (Figure 1—figure supplement 2A). In addition to wild-type (WT) α-syn, secretion of several PD-causing α-syn mutant proteins (A30P, E46K, and A53T) was also induced to differing levels by expression of DNAJC5 (Figure 1—figure supplement 2B-D).

In addition to the stimulated secretion of α-syn produced by the expression of exogenous DNAJC5, we examined the dependence of a basal secretion of α-syn on endogenous DNAJC5. We fused α-syn with an N-terminal nanoluciferase (Nluc) (England et al., 2016) for sensitive, quantitative detection (Figure 1—figure supplement 3A). Stimulated secretion of Nluc-α-syn by overexpression of DNAJC5 was confirmed by immunoblot, indicating that Nluc-fusion did not impede α-syn secretion (Figure 1—figure supplement 3B). Without overexpression of DNAJC5, we observed accumulation of Nluc-α-syn signal in the medium over time (Figure 1—figure supplement 3C).

Quercetin is a plant-derived flavonoid that has previously been shown to inhibit DNAJC5-mediated trafficking of a bacterial toxin (Figure 1—figure supplement 3D; Deruelle et al., 2021). We found that quercetin also inhibited Nluc-α-syn secretion in a dose-dependent manner (Figure 1—figure supplement 3E), implying a role for endogenous DNAJC5 in α-syn secretion. To exclude the off-target effect of quercetin, we created a DNAJC5 CRISPR knockout (KO) cell line (Figure 1—figure supplement 3F). Balfilomycin A1 (BaFA1), a lysosomal ATPase inhibitor, has been shown to stimulate α-syn secretion (Figure 1—figure supplement 3G; Buratta et al., 2020; Fernandes et al., 2016). BaFA1 is also known to stimulate the fusion of lysosomes and multivesicular bodies at the cell surface with the secretion of lysosomal content and exosomes (Cashikar and Hanson, 2019; Hikita et al., 2018; Tapper and Sundler, 1995). BaFA1-stimulated α-syn secretion was confirmed in WT HEK293T cells but substantially reduced in DNAJC5 KO cells (Figure 1—figure supplement 3H). Our results suggest that DNAJC5 is required for the secretion of α-syn from the endosome/lysosome and is enhanced by overexpression of DNAJC5.

Characterization of extracellular DNAJC5 and α-syn

In our established assay, DNAJC5 and α-syn co-secrete into the medium (Figure 1E). Secreted α-syn has been reported to be encapsulated inside EVs (Danzer et al., 2012). We sought to assess the EV association of secreted α-syn using a medium fractionation protocol based on EV preparations developed by our lab (Figure 2A; Shurtleff et al., 2016). After serial differential centrifugation, α-syn and NP-DNAJC5 remained soluble. In comparison, P-DNAJC5 co-sedimented with other EV markers after 100k×g centrifugation (Figure 2B). In addition to WT α-syn, we conducted medium fractionation with several PD-causing α-syn mutants and found they all remained soluble in culture supernatant fractions (Figure 2—figure supplement 1A). To test the EV association of P-DNAJC5, we performed a further sucrose step gradient flotation (Figure 2—figure supplement 2A) with the 100k high-speed pellet fraction (Figure 2—figure supplement 2B). P-DNAJC5 equilibrated with other EV markers to the 10%/40% interface expected for buoyant EVs (Figure 2—figure supplement 2B). We conclude that the secreted α-syn induced by DNAJC5 is neither membrane bound nor in a sedimentable fibrillar form.

Figure 2. Characterization of secreted α-syn.

(A) Medium fractionation scheme. (B) Secreted α-syn was soluble. Differential centrifugation was performed with conditioned medium from HEK293T cells transfected with DNAJC5 and α-syn. Alix and CD9, exosome markers. PDI, an endoplasmic reticulum (ER) marker, was used as exosome-negative control. (C) Gel filtration fractionation of medium. Conditioned medium was concentrated and subjected to gel filtration fractionation. Fractions were evaluated by anti-α-syn immunoblot. (D) Chromatograms of tandem α-syn monomer (blue curve), dimer (green curve), and tetramer (red curve) were overlaid. In comparison, the relative intensity of secreted α-syn in each fraction was plotted as blue bars. (E) Schematic diagram of co-immunoprecipitation (co-IP) of secreted α-syn and FLAG-α-syn. Shown here is possible interaction between α-syn (blue circle) and FLAG-α-syn (yellow circle) in a representative tetrameric conformation. (F) Anti-FLAG immunoprecipitation (FLAG-IP) of media from cells transfected with indicated plasmids. Both the medium input and FLAG-IP samples were evaluated with anti-α-syn immunoblot (anti-α-syn WB).

Figure 2—source data 1. Uncropped immunoblot corresponding to Figure 2.

Figure 2.

Figure 2—figure supplement 1. Solubility of secreted α-syn variants.

Figure 2—figure supplement 1.

(A) Medium fractionation of secreted α-syn PD mutants (A30P, E46K, and A53T). After differential centrifugation of medium, supernatant (10ks and 100ks) and pellet fractions (100kp) were evaluated by immunoblot. (B) Medium fractionation of basal secreted Nluc-α-syn without DNAJC5 overexpression. Similar fractionation assay was performed in (A) with medium from HEK293T cells transfected with Nluc-α-syn alone. Secreted Nluc-α-syn was quantified with a nanoluciferase assay. AU, arbitrary unit.
Figure 2—figure supplement 1—source data 1. Uncropped immunoblot images corresponding to Figure 2—figure supplement 1.
Figure 2—figure supplement 2. DNAJC5 enriched in buoyant EV fraction.

Figure 2—figure supplement 2.

(A) Schematic diagram of EV flotation protocol. Briefly, high-speed pellet fractions of growth medium were resuspended in 60% sucrose buffer and overlaid sequentially with 40% and 10% sucrose buffer. The tubes were centrifuged at 150,000 (150k)×g at 4°C for overnight. Buoyant EVs floated at the 10%/40% sucrose interface, separated from other insoluble materials. (B) Immunoblots across the sucrose step gradient. DNAJC5 as well as other classical exosome markers (Flot-2, CD63, and CD9) were highly enriched in fractions 4–6 at the 10%/40% interface.
Figure 2—figure supplement 2—source data 1. Uncropped immunoblot images corresponding to Figure 2—figure supplement 2.
Figure 2—figure supplement 3. Assessment of tandem α-syn oligomers by gel filtration chromatography.

Figure 2—figure supplement 3.

(A) Chromatogram of purified tetrameric α-syn tandem oligomer (α-syn-α-syn-α-syn-α-syn). (B) Coomassie-blue stained SDS-PAGE of fractions from gel filtration of tetramericα-syn tandem oligomer (α-syn-α-syn-α-syn-α-syn). (C) Chromatogram of purified dimeric α-syn tandem oligomer (α-syn-α-syn). (D) Coomassie-blue stained SDS-PAGE of fractions from gel filtration of dimericα-syn tandem oligomer (α-syn-α-syn). (E) Chromatogram of purified WT α-syn (α-syn). (F) Coomassie-blue stained SDS-PAGE of fractions from gel filtration of WTα-syn (α-syn).
Figure 2—figure supplement 3—source data 1. Uncropped gel images corresponding to Figure 2—figure supplement 3.

Next, we sought to characterize the conformation of secreted soluble α-syn. The medium-containing secreted α-syn was pooled, concentrated, and applied to a gel filtration column. Extracellular α-syn eluted from the column at around 60% of the column volume (Figure 2C), similar to the elution volume of purified monomeric α-syn (Figure 2D and Figure 2—figure supplement 3E, F). By an orthogonal assay, we examined the interaction between tagged and untagged forms of secreted α-syn as an indicator of oligomerization. In this assay, equal amounts of plasmids expressing FLAG-tagged α-syn and non-tagged α-syn were co-transfected in HEK293T cells and the medium was collected and incubated with anti-FLAG M2 beads to detect co-immunoprecipitation of the two forms (IP) (Figure 2E). FLAG-tagged α-syn migrated more slowly than non-tagged α-syn as detected in samples of the culture medium (Figure 2F). We found that only the FLAG-tagged α-syn was immuno-precipitated (Figure 2F), suggesting no stable interaction between the two species. The gel filtration and IP assays reinforced our conclusion that α-syn is secreted as a monomer.

Secretion of α-syn requires palmitoylation of DNAJC5

Membrane targeting of DNAJC5 is dependent upon palmitoylation (Greaves et al., 2008). Two specific mutations, L115R and L116Δ in the CS domain, cause adult-onset neuronal ceroid lipofuscinosis (NCL), a type of neurodegenerative disorder (Benitez et al., 2011). NCL mutations reduce the level of DNAJC5 palmitoylation and promote aggregation of the protein (Diez-Ardanuy et al., 2017). We perturbed DNAJC5 palmitoylation by either introducing the palmitoylation-deficient mutation L115R or treating cells with the competitive palmitoyl transferase inhibitor, 2-bromopalmitic acid (2-BA) (Resh, 2006), and subsequently examined the influence on DNAJC5 membrane association. DNAJC5 palmitoylation largely decreased in the L115R mutant or upon 2-BA treatment. Correspondingly, NP-DNAJC5 accumulated in the cytosol (Figure 3A and B).

Figure 3. Disruption of palmitoylation of DNAJC5 inhibited α-syn secretion.

(A) Inhibition of DNAJC5 palmitoylation by 2-bromopalmitic acid (2-BA) or introduced mutation L115R. Cellular fractionation was performed with HEK293T cells transfected with WT DNAJC5 and treated with 10 μm 2-BA, or transfected with DNAJC5 L115R mutant. C, cytosol; M, membrane; PNS, post-nuclear supernatant; TFR, transferrin receptor. (B) Quantification of the percentage of P-DNAJC5 and NP-DNAJC5 in different conditions as shown in (A). Error bars represent standard deviations of three experiments. (C) α-syn secretion was blocked with 2-BA treatment. HEK293T cells transfected with indicated plasmids were treated with DMSO or 10 μm 2-BA. Media fractions were collected and secretion was evaluated by SDS-PAGE and immunoblot. (D) Palmitoylation of DNAJC5 was blocked in HEK293T cells treated with 2-BA. (E) Quantification of normalized α-syn secretion in HEK293T cells after 2-BA treatment. The quantification was based on immunoblot in (C) and (D). The α-syn secretion was calculated as the amount of α-syn in media divided by the amount in lysate. (F) Quantification of normalized DNAJC5 secretion in HEK293T cells after 2-BA treatment. The quantification was based on immunoblot in (C) and (D). The DNAJC5 secretion was calculated as the amount of DNAJC5 in media divided by the amount in lysate. (G) DNAJC5 L115R mutant reduced α-syn secretion compared with WT DNAJC5. Secretion assay with HEK293T cells transfected with indicated plasmids encoding DNAJC5 variant was performed similar to (C). (H) DNAJC5 L115R was non-palmitoylated in HEK293T cells. (I) Quantification of normalized α-syn secretion in HEK293T cells transfected with DNAJC5 L115R mutant. The quantification was based on immunoblot in (G) and (H). (J) Quantification of normalized DNAJC5 secretion in HEK293T cells transfected with DNAJC5 L115R mutant. The quantification was based on immunoblot in (G) and (H).

Figure 3—source data 1. Uncropped immunoblot corresponding to Figure 3.

Figure 3.

Figure 3—figure supplement 1. Dose-dependent inhibition of α-syn secretion by 2-bromopalmitic acid (2-BA).

Figure 3—figure supplement 1.

(A) Chemical structure of palmitoylation inhibitor 2-bromopalmitic acid (2-BA). The single bromo substituent at position 2 is highlighted by a red dashed square. (B) α-syn secretion in the medium was inhibited by 2-BA in a dose-dependent manner. About 10 μm 2-BA was serially diluted by DMSO into 5 μm, 2 μm, and 1 μm solution. HEK293T cells were first transfected with DNAJC5 and α-syn. After medium replacement, 2-BA of indicated concentration was added to cell culture. Media were collected after 36 hr and followed by sample preparation, SDS-PAGE and immunoblot. (C) With increasing concentration of 2-BA, P-DNAJC5 decreased and NP-DNAJC5 increased in HEK293T cells. (D) Quantification of normalized α-syn secretion upon increasing concentration of 2-BA. Quantification was based on immunoblot in (B) and (C). The α-syn secretion was calculated as the amount of α-syn in media divided by the amount in lysate. (E) Quantification of ratio of P-DNAJC5/NP-DNAJC5. The quantification was based on immunoblot in (C).
Figure 3—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 3—figure supplement 1.
Figure 3—figure supplement 2. Blockage of USP19-induced α-syn secretion by DNAJC5 L115R or L116Δ mutant.

Figure 3—figure supplement 2.

(A) USP19 induced α-syn secretion in the medium, which was further enhanced by WT DNAJC5 and blocked by two DNAJC5 palmitoylation-deficient mutants (L115R and L116Δ). (B) Both mutations, L115R and L115Δ, inhibited DNAJC5 palmitoylation in HEK293T cells. (C) Quantification of normalized α-syn secretion in HEK293T cell transfected with indicated constructs. The quantification was based on immunoblot in (A) and (B). α-Syn secretion was calculated as the amount of α-syn in media divided by the amount in lysate.
Figure 3—figure supplement 2—source data 1. Uncropped immunoblot corresponding to Figure 3—figure supplement 2.
Figure 3—figure supplement 3. Golgi retention of DNAJC5 in secretion-deficient conditions.

Figure 3—figure supplement 3.

(A) Immunofluorescence (IF) images of U2OS cells transfected with wildtype (WT) DNAJC5-HaloTag. Before fixation, HaloTag TMR ligands were added to the cell culture to label DNAJC5. Golgi apparatus was visualized by IF using anti-GM130 antibody. Nuclei were stained with DAPI. Scale bar: 10 μm. (B) IF images of U2OS cells transfected with DNAJC5 (L115R)-HaloTag. Same staining procedure was performed as in (A). Scale bar: 20 μm. (C) IF images of U2OS cells transfected with WT DNAJC5-HaloTag and treated with 5 μM 2-BA. After transfection with WT DNAJC5-HaloTag, cells were incubated with 5 μM 2-BA for 1 day to block palmitoylation of DNAJC5. Same staining procedure was performed as in (A). Scale bar: 10 μm.

Having confirmed palmitoylation inhibition by 2-BA and the L115R mutation, we next examined their effect on α-syn secretion. Upon 10 μM 2-BA treatment, α-syn and DNAJC5 secretion were abolished (Figure 3C, E, F). The efficacy of the inhibitor was validated by the disappearance of the low-mobility band corresponding to P-DNAJC5 in the cell lysate (Figure 3D). Furthermore, 2-BA inhibited DNAJC5 palmitoylation (Figure 3—figure supplement 1C, E) and α-syn secretion in a concentration-dependent manner (Figure 3—figure supplement 1B, D). Likewise, α-syn secretion was reduced by the palmitoylation-deficient DNAJC5 (L115R) compared with DNAJC5 (WT) (Figure 3G–J). DNAJC5 has been proposed to function downstream of the deubiquitinase USP19 in the MAPS pathway (Xu et al., 2018). In agreement with the model, DNAJC5 carrying either NCL mutation L115R or L116Δ had no palmitoylated protein band detected in the lysate (Figure 3—figure supplement 2B) and blocked USP19-stimulated α-syn secretion (Figure 3—figure supplement 2A, C). These results establish that palmitoylation is essential for DNAJC5 membrane association and function in stimulating α-syn secretion.

A previous study reported an altered distribution of DNAJC5 mutant protein to the Golgi apparatus and cytosol (Nosková et al., 2011). In confocal immunofluorescence (IF) images, we confirmed that WT DNAJC5 did not colocalize with the Golgi marker GM130, whereas both the L115R mutant and 2-BA treated WT cells partially retained DNAJC5 in puncta coincident with the Golgi marker GM130 (Figure 3—figure supplement 3A, B, C). We conclude that α-syn secretion depends upon an appropriate subcellular organelle localization of DNAJC5.

DNAJC5-dependent internalization of α-syn into enlarged endosomes

DNAJC5 has been reported under normal conditions to be associated with late endosomes (Lee et al., 2018). Using confocal IF, we found colocalization between endogenous DNAJC5 and the late-endosomal marker CD63 (Figure 4—figure supplement 1A). To visualize the topological localization of DNAJC5 and α-syn inside or outside endosomes, we turned to a U2OS cell line expressing a fluorescent protein-fused, constitutively active form of Rab5 (Rab5Q79L) (Bohdanowicz et al., 2012). As a positive control, CD63 localized to the lumen of enlarged endosomes labeled by mCherry-Rab5Q79L (Figure 4—figure supplement 1B). We labeled DNAJC5 with the self-labeling HaloTag for multiple choices of color in live-cell imaging (Los et al., 2008). Both diffuse and punctate DNAJC5 localized to the lumen of enlarged endosomes (Figure 4A). Unlike WT DNAJC5, the DNAJC5 L115R mutant became disperse in the cytosol, rather than being internalized into enlarged endosomes (Figure 4—figure supplement 2A). In contrast, mNeonGreen (mNG)-fused α-syn showed diffuse localization in both the cytosol and nucleus but was completely excluded from enlarged endosomes in L115R mutant cells (Figure 4B). Notably, we observed the entry of α-syn into enlarged endosomes containing internalized DNAJC5, implying the translocation of α-syn into the membrane compartment required DNAJC5 (Figure 4C). The ratio of α-syn-containing endosomes in cells increased significantly with DNAJC5 overexpression (Figure 4H). With no luminal localization inside enlarged endosomes, the DNAJC5 L115R mutants also failed to induce entry of α-syn into the same compartments (Figure 4—figure supplement 2B). As an independent test of the localization suggested by the imaging results, we applied cell fractionation to separate membranes of DNAJC5- and α-syn-expressing cells (Figure 4D). Both DNAJC5 and α-syn were enriched in a 25k membrane pellet fraction (Figure 4E). In a protease protection assay with 25k sedimented membranes, we found that α-syn and DNAJC5 were partially resistant to digestion by proteinase K in the absence but not in the presence of Triton X-100 consistent with the conclusion that about half of the proteins were sequestered within membrane compartments (Figure 4F and G). Our visual inspection and quantification results are consistent with a membrane translocation role for DNAJC5 prior to α-syn secretion.

Figure 4. Topological localization of α-syn and DNAJC5 in enlarged endosomes.

(A) DNAJC5 was internalized inside enlarged endosomes. Live U2OS cells expressing mCherry-Rab5Q79L (red) showed circular enlarged endosomes labeled by Rab5 mutant. DNAJC5-HaloTag (green) was visualized by addition of HaloTag Oregon Green Ligand. Representative enlarged endosomes show diffuse (1) or punctate (2 and 3) internalized DNAJC5. Scale bar: 15 μm in overviews and 1 μm in magnified insets. (B) α-syn was excluded from enlarged endosomes. In live U2OS cells, expression of BFP-Rab5Q79L (blue) produced enlarged endosomes of similar morphology compared with mCherry-Rab5Q79L. mNeonGreen-α-syn (mNG-α-syn, green) was expressed both in the nucleus and cytosol. No mNG-α-syn was found inside enlarged endosomes (1–3). Scale bar: 20 μm in overviews and 1 μm in magnified insets. (C) α-syn enters into enlarged endosomes in the presence of DNAJC5. DNAJC5-HaloTag (red) and mNG-α-syn (green) were coexpressed in U2OS cells carrying BFP-Rab5Q79L (blue) mutant and imaged. No mNG-α-syn was internalized in endosome without DNAJC5-HaloTag inside (1). In contrast, mNG-α-syn was found inside endosomes with DNAJC5-HaloTag inside (2 and 3). Scale bar: 10 μm in overviews and 1 μm in magnified insets. (D) α-syn and DNAJC5 co-sedimented in membrane fractionation. HEK293T cell homogenate was sequentially centrifuged at increasing velocity from 3000×g (3k), 25,000×g (25k), and 100,000×g (100k). The 25k membrane fraction had the highest amount of both α-syn and DNAJC5. (E) Quantification of the membrane fractionation results in (D). (F) Proteinase K protection assay of 25k membrane-containing α-syn and DNAJC5. (G) Quantification of the proteinase K protection assay in (F). (H) Quantification of the ratio of α-syn-containing endosomes in control cells (no-DNAJC5 transfection) or cells co-transfected with DNAJC5. More than 100 enlarged endosomes were counted in each group. Error bars represent standard deviations. P value<0.0001, two-tailed t test.

Figure 4—source data 1. Uncropped immunoblot corresponding to Figure 4.

Figure 4.

Figure 4—figure supplement 1. Immunofluorescence (IF) images of endogenous DNAJC5 and enlarged endosomes.

Figure 4—figure supplement 1.

(A) Colocalization between endogenous CD63 (red) and DNAJC5 (green). U2OS cells were cultured and fixed, incubated with corresponding antibodies for IF detection of endogenous CD63 and DNAJC5. Representative colocalized region is shown in magnified insets. Scale bar: 20 μm. (B) CD63 (green) was inside the enlarged endosomes labeled by peripheral mCherry-Rab5Q79L (red). U2OS expressing mCherry-Rab5Q79L were fixed, followed by IF using anti-CD63 antibody. Scale bar: 25 μm.
Figure 4—figure supplement 2. Live-cell images of U2OS cells expressing DNAJC5 L115R mutant and α-syn.

Figure 4—figure supplement 2.

(A) Live-cell imaging of U2OS cells transfected with DNAJC5 (L115R)-HaloTag and mCherry-Rab5Q79L. DNAJC5 (L115R)-HaloTag (green) is diffuse in cytosol and outside of the enlarged endosomes labeled by peripheral mCherry-Rab5Q79L (red). Scale bar: 10 μm in overviews and 1 μm in magnified insets. (B) Live-cell imaging of U2OS cells transfected with mNeonGreen (mNG)-α-syn, DNAJC5 (L115R)-HaloTag, and mCherry-Rab5Q79L. In the condition of coexpression with DNAJC5 (L115R)-HaloTag (red), no mNG-α-syn (green) was found inside of enlarged endosomes labeled by peripheral BFP-Rab5Q79L (blue). Scale bar: 10 μm in overviews and 1 μm in magnified insets.
Figure 4—video 1. Time lapse of movement of internalized α-syn and DNAJC5 in the enlarged endosomes.
Download video file (28MB, mp4)
DNAJC5-HaloTag (red) and mNG-α-syn (green) were coexpressed in U2OS cells carrying BFP-Rab5Q79L (blue) mutant and imaged. Scale bar: 10 μm.

Size and unfolding are dispensable for α-syn secretion

In our medium fractionation assay, secreted α-syn in the extracellular space was characterized as a soluble monomer (Figure 2). We generated a series of tandem repeats of α-syn to mimic its oligomeric states (Figure 5A; Dong et al., 2018). On SDS-PAGE, α-syn tandem repeats showed a larger apparent size than their predicted molecular weights, possibly caused by their extended conformation as intrinsically disordered proteins (Figure 2—figure supplement 2). We first determined that these α-syn tandem repeats could also be secreted upon overexpression of DNAJC5 (Figure 5B), indicating that DNAJC5 can accommodate α-syn of different sizes. Fractionation of the growth medium showed that secreted tandem repeats were also soluble (Figure 5—figure supplement 1).

Figure 5. Secretion of tandem α-syn oligomers and α-syn fused with thermostable helix-bundle protein.

(A) Schematic diagrams of tandem α-syn oligomers. α-syn protomers (yellow) were linked head to tail by flexible linker (green) to mimic increased size of α-syn oligomers. (B) Secretion of tandem α-syn oligomers in medium. Secretion assay was performed with media from HEK293T cells transfected with indicated tandem α-syn oligomers. Tandem α-syn oligomers are more sensitively detected by immunoblot which were exposed for shorter time compared with WT α-syn. (C) Expression of tandem α-syn oligomers in HEK293T cells. *a non-specific band. (D) Schematic diagrams of N-terminal fused and C-terminal fused thermostable three helix-bundle (3H-) α-syn. 3H shown as three blue dashes, α-syn shown as orange circle. (E) Secretion of 3H-α-syn and α-syn-3H in medium. Secretion assay was performed with media from HEK293T cells transfected with indicated 3H-fused α-syn constructs. *a non-specific band. (F) Expression of 3H-α-syn and α-syn-3H in HEK293T cells. *a non-specific band.

Figure 5—source data 1. Uncropped immunoblot corresponding to Figure 5.

Figure 5.

Figure 5—figure supplement 1. Medium fractionation of secreted tandem α-syn oligomers.

Figure 5—figure supplement 1.

Medium fractionation of secreted tandem α-syn oligomers. P-DNAJC5 was depleted in the supernatant after centrifugation at 100,000 (100k)×g. However, no significant decrease of tandem α-syn oligomers in the supernatant was observed.
Figure 5—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 5—figure supplement 1.
Figure 5—figure supplement 2. Thermostable three helix bundle blocked pOTC-mediated mitochondrial import of GFP.

Figure 5—figure supplement 2.

(A) Schematic diagrams of constructs used in mitochondrial import assay. GFP, GFP alone. pOTC-GFP, GFP with leader peptide from ornithine ranscarbamylase (OTC) fused at amino-terminus. pOTC-3H-GFP, the thermostable three helix bundle was inserted between the leader peptide pOTC and GFP. (B) Immunoblot analysis of proteins in crude mitochondria fraction. Whole-cell lysate (W) was prepared by mixing homogenized cells with equal volume of 2.3 M sucrose buffer and centrifugation at 1200×g to remove large debris. Soluble fraction (S) and particulate fraction (P) were separated by centrifuging W fraction at 7000×g for 10 min. Mitochondria were enriched in P fraction. Tom20, mitochondrial marker. Tubulin, soluble marker. (C) The mitochondrial localization efficiency was calculated by quantifying the protein amount in P fraction divided by the amount in S fraction. (D) Cartoon depicting relative localization of proteins inside or outside of mitochondria. Tom20, a mitochondrial outer membrane protein. Citrate synthase (CS), a mitochondrial matrix protein. The import of pOTC-3H-GFP is blocked by 3H. (E) Proteinase K protection assay of crude mitochondria. SDS (0.5%) was added in addition to 1% TX-100 to sensitize protease treatment of well-folded protein, for example, CS. The protease accessibility of pOTC-3H-GFP was revealed by the production of GFP fragment and disappearance of the full-length (FL) band. (F) Quantification of percentage of protection of proteins in (E).
Figure 5—figure supplement 2—source data 1. Uncropped immunoblot corresponding to Figure 5—figure supplement 2.

In conventional and many unconventional secretion processes, the secreted proteins undergo unfolding prior to translocation through a narrow channel across the hydrophobic membrane barrier (Rapoport et al., 2017). Recent progress in protein design has allowed the synthesis of super-folded protein constructs (Kuhlman and Bradley, 2019). For example, a three helix-bundle protein (3H) designed in the lowest-energy arrangements displayed extreme thermodynamic stability and remained folded even in non-physiological denaturing conditions (Huang et al., 2014). Given that mitochondrial protein import is dependent on protein unfolding (Neupert, 1997), we tested the effect of 3H insertion on the import of mitochondrial matrix enzyme ornithine transcarbamylase (OTC) (Horwich et al., 1985; Yano et al., 1997). As a control, we created a pOTC leader peptide fused to GFP (Figure 5—figure supplement 2A). pOTC-GFP was enriched in a mitochondria-containing particulate (P) fraction compared to non-tagged GFP. However, a construct in which 3H was inserted between the leader sequence and GFP resulted in 80% of the fusion protein retained in the soluble fraction (Figure 5—figure supplement 2B, C). We then used proteinase K protection to assess the topology of pOTC-3H-GFP associated with crude mitochondria (Figure 5—figure supplement 2D). About 80% of citrate synthase (CS), a known mitochondria matrix protein, was protected from proteinase K. In contrast, neither the mitochondrial outer membrane protein Tom20 nor pOTC-3H-GFP was protected, suggesting 3H prevented the translocation of GFP into mitochondria (Figure 5—figure supplement 2E, F). Using a similar approach, we fused 3H to either the N- or C-terminus of α-syn to impede the unfolding process (Figure 5D). These α-syn fusion proteins were expressed and secreted normally into the growth medium (Figure 5E&F). These data suggest that protein unfolding is dispensable for α-syn secretion.

XPACK fusion rescues DNAJC5 L115R secretion deficiency by induced oligomerization

DNAJC5 has been reported to have an intrinsic propensity to form SDS-resistant oligomers (Zhang and Chandra, 2014). In a whole gel immunoblot of extracellular DNAJC5, we noticed many diffuse, ladder-like bands that migrated more slowly than the two corresponding to P-DNAJC5 and NP-DNAJC5 (Figure 6A), possibly higher molecular weight (HMW) oligomers. This apparent oligomerization of DNAJC5 became more obvious when the J domain was deleted (Figure 6—figure supplement 1A). The migration of HMW-DNAJC5 was not altered in samples heated in the presence of a reducing agent (Figure 6—figure supplement 1B). To assess the size of these HMW species of DNAJC5, we evaluated a cell lysate by gel filtration chromatography. HMW-DNAJC5 fractionated according to its apparent size, forming a stair-like pattern on the DNAJC5 immunoblot (Figure 6B). HMW-DNAJC5 chromatographed within the gel filtration column volume, consistent with discrete protein species rather than aggregates (Figure 6B). These results suggest the presence of higher-order, SDS-resistant, non-disulfide-bonded DNAJC5 oligomers both in intracellular and extracellular fractions.

Figure 6. XPACK (XP)-induced DNAJC5 L115R oligomerization rescued α-syn secretion.

(A) Ladder pattern of higher molecular weight (HMW) DNAJC5 oligomers in the medium. Medium from HEK293T cell culture transfected with DNAJC5 was centrifuged at 1000 (1k)×g, 10,000 (10k)×g, and 100,000 (100k)×g, followed by SDS-PAGE and immunoblot of supernatant (s) fractions at each centrifugation step. (B) Fractionation of HMW-DNAJC5 with gel filtration. HEK293T cells transfected with DNAJC5 were lysed, clarified, and subjected to gel filtration. HMW-DNAJC5 of different sizes were separated based on their corresponding molecular weight. (C) XP-DNAJC5 L115R mutant forms a membrane-bound oligomer. Cellular fractionation was performed with HEK293T cells transfected with indicated DNAJC5 variants. Note the substantial change of electrophoretic mobility of XP-DNAJC5 L115R on SDS-PAGE. (D) α-syn secretion induced by XP-DNAJC5 L115R. Secretion assay was performed with HEK293T cells transfected with indicated plasmids. About 10 μm 2-BA was used to block induced α-syn. (E) Expression of α-syn and DNAJC5 variants in HEK293T cells. Note the substantial change in electrophoretic mobility of 2-BA-treated XP-DNAJC5 L115R on SDS-PAGE.

Figure 6—source data 1. Uncropped immunoblot corresponding to Figure 6.

Figure 6.

Figure 6—figure supplement 1. Characterization of HMW-DNAJC5 and XPACK fusion.

Figure 6—figure supplement 1.

(A) DNAJC5 (ΔJ) forms a series of SDS-resistant oligomers. HEK293T cells transfected with WT DNAJC5 or DNAJC5 (ΔJ) were lysed and evaluated by immunoblot using anti-DNAJC5 antibody. (B) HMW-DNAJC5 is not formed by non-specific disulfide bonds. HEK293T cells transfected with DNAJC5 were lysed for SDS-PAGE followed by immunoblot. The loading samples for SDS-PAGE were prepared with increasing amount of DTT up to 40 mM. (C) Schematic diagram of XPACK. XPACK is myristoylated on the first glycine (G) and palmitoylated on the second cystine (C). Replacement of Serine (S) at position 5 with a hydrophobic isoleucine (I) abolishes normal lipidation of XPACK. (D) Assessment of different XPACK fusion constructs. Cell lysate containing different DNAJC5 constructs were evaluated by anti-DNAJC5 immunoblot. (E) Membrane association of XP-DNAJC5 dependent on palmitoylation. HEK293T cells transfected with XP-DNAJC5 were treated with DMSO or 10 μM 2-BA. After cell culture for 24 hr, cellular fractionation was performed with homogenized cells. Distribution of XP-DNAJC5 in cytosol (C) and membrane (M) fractions were evaluated with immunoblot.
Figure 6—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 6—figure supplement 1.
Figure 6—figure supplement 2. Live-cell images of U2OS cells expressing XP-DNAJC5 L115R mutant and α-syn.

Figure 6—figure supplement 2.

(A) Internalization of punctate XP-DNAJC5 (green) into enlarged endosomes labeled by mCherry-Rab5Q79L (red). U2OS cells were transfected with XP-DNAJC5 and mCherry-Rab5Q79L. Live-cell imaging was performed 24 hr after transfection. Representative enlarged endosomes with XP-DNAJC5 are shown in magnified inset. Scale bar: 10 μm in overviews and 1 μm in magnified insets. (B) α-syn enters into enlarged endosomes in the presence of XP-DNAJC5. XP-DNAJC5-HaloTag (red) and mNG-α-syn (green) were coexpressed in U2OS cells carrying BFP-Rab5Q79L (blue) mutant and imaged. Representative enlarged endosome with both XP-DNAJC5-HaloTag and mNG-α-syn inside is shown in magnified inset. Scale bar: 10 μm in overviews and 1 μm in magnified insets. (C) Quantification of the ratio of α-syn-containing endosomes in cells co-transfect with DNAJC5 L115R or cells co-transfected with DNAJC5 XP-L115R. More than 100 enlarged endosomes were counted in each group. Error bars represent standard deviations. P value<0.0001, two-tailed t test.

XPACK (XP) is a membrane-targeting peptide sequence used widely in studies of cargo loading into exosomes and delivery to target cells of choice (Yim et al., 2016). The exosome loading process by XP is also dependent on two lipidation reactions—myristoylation on the first glycine and palmitoylation on the second cysteine (Figure 6—figure supplement 1C; Zacharias et al., 2002). Given the similarity of membrane localization and lipidation between XP and the CS domain of DNAJC5, we examined α-syn secretion in cells expressing an XP-DNAJC5 fusion. An N-terminal XP fusion (XP-WT) resulted in the expression of a species that migrated at the position of P-DNAJC5, in contrast to the two species representing P- and NP-DNAJC5 in the WT DNAJC5 sample (Figure 6—figure supplement 1D). Again in contrast to WT DNAJC5, XP-DNAJC5 was exclusively associated with the sedimentable membrane fraction (Figure 6—figure supplement 1E). This suggested that XP-mediated lipidation was highly efficient and possibly irreversible. Formation of the lower electrophoretic mobility and membrane-associated form of XP-DNAJC5 was blocked by 2-BA treatment, indicating XP lipidation included palmitoylation (Figure 6—figure supplement 1E). XP fusion to the palmitoylation-deficient mutant of DNAJC5 (L115R) did not produce a species that migrated at the position of P-DNAJC5 but resulted in several less abundant species that migrated between the positions of NP- and P-DNAJC5 (Figure 6—figure supplement 1D). We introduced a serine to leucine point mutation in the XPACK sequence which was predicted to block lipidation (dead XPACK, DXP) (Figure 6—figure supplement 1C). The DXP-DNAJC5 L115R species had the same mobility as NP-DNAJC5 (Figure 6—figure supplement 1D).

We conducted cellular fractionation on lysates of cells expressing DNAJC5 XP-L115R. XP-L115R was highly enriched in the membrane fraction, likely as a result of XPACK-mediated lipidation (Figure 6C). SDS-PAGE of XP-L115R released by detergent solubilization migrated slowly and remained near the top of the gel, suggesting XPACK-induced high-order oligomerization or aggregation (Figure 6C). In spite of the apparent difference between DNAJC5 XP-L115R and WT DNAJC5, α-syn secretion was stimulated by the expression of both species (Figure 6D). Treatment with the palmitoylation inhibitor 2-BA resulted in the formation of XP-L115R that migrated to a position similar to that of monomeric DNAJC5 (Figure 6E). Correspondingly, secretion of α-syn was no longer stimulated by the palmitoylation deficient DNAJC5 XP-L115R monomer (Figure 6D).

In order to expand on the fractionation results, we employed confocal microscopy to examine the subcellular localization of DNAJC5 XP-L115R fused with a C-terminal HaloTag. In contrast to the diffuse distribution of the DNAJC5 L115R mutant, which was excluded from the interior of enlarged endosomes (Figure 4—figure supplement 2A), punctate DNAJC5 XP-L115R was widely associated with enlarged endosomes (Figure 6—figure supplement 2A). Internalization events were found in several enlarged endosomes (Figure 6—figure supplement 2A, magnified insets). mNG-α-syn was also incorporated into endosomal compartments in cells coexpressing DNAJC5 XP-L115R (Figure 6—figure supplement 2B). The level of α-syn-containing endosomes in cells expressing DNAJC5 XP-L115R was ~2-fold higher than in cells expressing the DNAJC5 L115R mutant (Figure 6—figure supplement 2C). Our imaging data corroborate the biochemical similarity between WT DNAJC5 and DNAJC5 XP-L115R.

Secretion of endogenous α-syn from neurons is mediated by DNAJC5

To evaluate the function of DNAJC5 in α-syn secretion at physiological levels of expression in a neuronal cell line, we employed SH-SY5Y, a neuroblastoma line that differentiates in the presence of retinoic acid (RA) into nerve cells that express dopamine neuron (DA) markers including tyrosine hydroxylase (TH) (Lopes et al., 2010). We observed elevated levels of expression of α-syn and dopamine transporter (DAT) in SH-SY5Y cells after 6 days of RA-induced differentiation (Figure 7—figure supplement 1A). Fractionation of SH-SY5Y cell lysates resolved DNAJC5 into the low electrophoretic mobility P form associated with sedimentable membranes (M) and the non-sedimentable cytosolic NP form (Figure 7A). Hydroxylamine treatment of the membrane-associated form converted DNAJC5 to the electrophoretic mobility position of the NP form, as before (Figure 7—figure supplement 1B; Figure 1—figure supplement 1B).

Figure 7. Recapitulation of endogenous DNAJC5-mediated α-syn secretion in various neuronal cell cultures.

(A) Membrane and cytosol fractionation of differentiated SH-SY5Y neuroblastoma cells. The fractionation was performed as depicted in Figure 1B. C, cytosol; M, membrane. The distribution of endogenous DNAJC5 and α-syn was evaluated by immunoblot. Transferrin receptor (TFR) was used as a membrane marker. Tubulin was used as a cytosol marker. (B) Quantification of α-syn level in the supernatant of centrifuged media with ELISA. Conditioned media were collected and sequentially centrifuged at 1000 (1k)×g, 10,000 (10k)×g, and 100,000 (100k)×g. The supernatant from each centrifugation step (1ks, 10ks, and 100ks) was collected and measured by LEGEND MAX Human α-synuclein (Colorimetric) ELISA Kit. One-way ANOVA showed no significant (ns) difference of α-syn level between fractions. (C) Quercetin inhibited endogenous α-syn secretion in hiPSC-derived midbrain dopamine neurons. hiPSC-dopamine neurons carrying the GBA-N370S mutation were treated with quercetin (5 μM or 10 μM) at day 35. Culture media samples were harvested after 3 days treatment at day 38 and α-syn levels in the media were analyzed by electro-chemiluminescent immunoassay. Data points represent individual cell lines derived from different donors and are normalised to total protein in the corresponding cell lysates. One-way ANOVA followed by Tukey’s post hoc test shows a significant reduction in α-syn secretion with increasing quercetin concentration (*p<0.05, **p<0.01). (D) Depletion of endogenous DNAJC5 in SH-SY5Y cells decreased basal α-syn secretion. After 3 days of culture, the media from differentiated SH-SY5Y cells transduced with shRNA targeting GFP (shRNA-GFP) or shRNA targeting DNAJC5 (shRNA-DNAJC5) were collected and the extracellular α-syn was quantified with ELISA. P value<0.0002, two-tailed t test. (E) Expression of exogenous human DNAJC5 in mouse mDA stimulated basal α-syn secretion. WT mDA and mDA expressing hDNAJC5 were treated with DMSO or 100 nM BaFA1. Quantification of α-syn in conditioned media was performed with Mouse α-synuclein ELISA Kit (Abcam). α-syn secretion was normalized by dividing the α-syn in media (pg/ml) by the α-syn in cell lysates (ng/ml). P value<0.01, one-way ANOVA. (F) BaFA1 increased DNAJC5 oligomerization in mouse mDA neurons.

Figure 7—source data 1. Uncropped immunoblot corresponding to Figure 7.

Figure 7.

Figure 7—figure supplement 1. Basal α-syn secreted as a soluble form from differentiated SH-SY5Y.

Figure 7—figure supplement 1.

(A) Differentiation of SH-SY5Y was initiated by lowering the serum concentration to 1% FBS and addition of 10 µM retinoic acid (RA). Media were replaced every 3 days and the cells were harvested at indicated time to examine the expression of neuronal marker. DAT, dopamine transporter; Tuj1, neuron-specific class III β-tubulin. (B) In vitro depalmitoylation assay of endogenous DNAJC5 in differentiated SH-SY5Y cells. The depalmitoylation assay was performed as in Figure 1—figure supplement 1B using membrane (M) fraction from SH-SY5Y cells. HA, hydroxylamine. (C) Proteinase K protection assay of 100,000 (100k) pellet fraction from the centrifuged media of differentiated SH-SY5Y culture. Flot-2 and CD63 were used as exosome markers. (D) Sedimented α-syn was not buoyant. 100k pellet from (C) was mixed with 60% sucrose in PBS and layered with 40% and 20% sucrose in PBS sequentially. After centrifuged at 150,000×g for 16 hr, fractions were collected from top to bottom.
Figure 7—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 1.
Figure 7—figure supplement 2. Differentiation of human induced pluripotent stem cells (hiPSCs) and palmitoylation of DNAJC5.

Figure 7—figure supplement 2.

(A) Schematic of the differentiation protocol used to generate hiPSC-derived dopamine neurons, including a patterning phase to generate neural progenitor cells followed by differentiation into mature neurons. Green arrows represent points of replating when cells are supplemented with ROCK inhibitor (Ri) to increase survival. BDNF, brain-derived neurotrophic factor; FGF8a, fibroblast growth factor 8a; GDNF, glial cell line-derived neurotrophic factor; Puro, puromorphamine; SHH, sonic hedgehog; TGF-β3, transforming growth factor beta 3 (see Kriks et al., 2011; Beevers et al., 2017; Lang et al., 2019 for full details). Neurons are mature and harvested between 35 and 68 days for analysis. Immunocytochemical fluorescent images of mature neurons at day 50 stained for neuronal marker microtubule-associated protein (MAP2), the dopaminergic marker tyrosine hydroxylase (TH), and DAPI. Scale bar: 20 µm. (B) DNAJC5 is palmitoylated in iPSC-derived dopamine neurons. Immunoblot analysis of DNAJC5 palmitoylation in hiPSC-derived dopamine neurons treated with DMSO, 7.5 μM Quercetin or 10 μM 2-BA on day 65 and harvested on day 68. TH was used as a marker of dopaminergic identity. (C) Partial depalmitoylation of DNAJC5 by 2-BA in iPSC-derived dopamine neurons does not reduce α-syn secretion. hiPSC-derived dopamine neurons carrying the GBA-N370S mutation were treated with palmitoylation inhibitor 2-BA (5 μM or 10 μM) at day 35. Culture media samples were harvested after 3 days treatment at day 38 and α-syn levels in the media were analyzed by electro-chemiluminescent immunoassay. Data points represent individual cell lines derived from different donors and are normalized to total protein in the corresponding cell lysates. One-way ANOVA shows no effect of 2-BA on α-syn secretion.
Figure 7—figure supplement 2—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 2.
Figure 7—figure supplement 3. shRNA-mediated DNAJC5 knockdown in differentiated SH-SY5Y cells.

Figure 7—figure supplement 3.

(A) Examination of knockdown efficiency by shRNA targeting DNAJC5 in HEK293T cells. (B) Endogenous DNAJC5 expression decreased in SH-SY5Y cells transduced with shRNA targeting DNAJC5.
Figure 7—figure supplement 3—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 3.
Figure 7—figure supplement 4. Differentiation of mouse embryonic stem cells (mESCs) and expression of human DNAJC5.

Figure 7—figure supplement 4.

(A) Schematic overview of protocol used for differentiation of mESCs into middle-brain dopaminergic (mDA) neuronal cultures. Immunocytochemical staining using stem cell markers (Nanog, Sox2), neuronal precursor marker (Nestin), mDA markers [FoxA2, Nurr1, Lmx1a, Sox6 (selective marker of substantia nigra pars compacta lineage), TH (tyrosine hydroxylase), Girk2 (G-protein-regulated inward-rectifier potassium channel 2, expressed in DA neurons)], neuronal marker (Tuj1) and nuclear marker (dapi). (B) Expression of human DNAJC5 with C-terminal FLAG tag in mDA neurons.
Figure 7—figure supplement 4—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 4.

We employed a sensitive α-syn enzyme-linked immunosorbent assay (ELISA) and detected about 300 pg/ml α-syn secreted into the supernatant of RA-differentiated SH-SY5Y cells (Førland et al., 2018; Figure 7B). Differential centrifugation of the medium fraction demonstrated that the bulk of the secreted α-syn remained soluble (Figure 7B). A 100k pellet fraction was probed by protease protection for the localization of Flot-2, an exosome marker and DNAJC5. Both were resistant to degradation by proteinase K in the absence but not in the presence of TX-100, suggesting that both were protected within the lumen of EVs (Figure 7—figure supplement 1C). In contrast, residual full-length (FL) α-syn in the pellet fraction was cleaved by proteinase K without or with detergent (Figure 7—figure supplement 1C). As an additional test, sucrose gradient flotation of the high-speed pellet fraction as used in Figure 2—figure supplement 2A revealed that α-syn secreted by differentiated SH-SY5Y cells was not buoyant whereas DNAJC5 appeared associated with membranes fractionating at the position of EVs (Figure 7—figure supplement 1D). Thus, as with HEK293T cells, α-syn secreted by differentiated SH-SY5Y cells appears not to be enclosed within EVs.

Midbrain dopamine (mDA) neurons (Figure 7—figure supplement 2A) differentiated from human-induced pluripotent stem cells (hiPSCs) from Parkinson’s patients with the GBA-N370S mutation, a genetic lesion that causes ER stress and dysfunctional lysosomes, release about twice the level of α-syn compared to control WT neurons (Fernandes et al., 2016; Lang et al., 2019). Treatment of GBAN370S hiPSC-derived dopamine neurons with the DNAJC5 inhibitor quercetin led to a significant dose-dependent reduction in the secretion of endogenous α-syn (Figure 7C). Immunoblotting of hiPSC-derived dopamine neuron lysate revealed that the endogenous DNAJC5 is natively palmitoylated which can be partially reduced by treatment with 2-BA (10 μM) to induce the formation of the lower, non-palmitoylated band (Figure 7—figure supplement 2B). However, this partial de-palmitoylation of DNAJC5 was insufficient to inhibit α-syn release by iPSC-derived GBA-N370S dopamine neurons at the concentration of 2-BA used (Figure 7—figure supplement 2C).

To examine the role of DNAJC5 in differentiated SH-SY5Y cells, we silenced the expression of the chromosomal locus by small hairpin RNAs (shRNAs) transduced by lentivirus. The efficiency of shRNA targeting DNAJC5 was confirmed by knockdown (KD) of endogenous DNAJC5 in HEK293T cells (Figure 7—figure supplement 3A). Similarly, DNAJC5 was successfully depleted in differentiated SH-SY5Y cells (Figure 7—figure supplement 3B). As a result, secretion of α-syn was reduced fivefold compared with a control transduced with shRNA targeting GFP (Figure 7D).

In HEK293T cells, overexpression of DNAJC5 increased α-syn secretion (Figure 1E). We were unable to observe enhanced secretion of α-syn in SH-SY5Y overexpressing DNAJC5, possibly because of a high level of expression of endogenous DNAJC5 in the differentiated cells (data not shown). To test the effect of DNAJC5 on the basal level of α-syn secretion in neurons, we stably transduced mouse embryonic stem cells (mESCs) with lentivirus-containing human DNAJC5 WT or L115R and differentiated them into mDA neurons (Figure 7—figure supplement 4A). After differentiation, DNAJC5 WT was expressed in mDA, but we were unable to detect the expression of DNAJC5 L115R (Figure 7—figure supplement 4B). Analysis of conditioned media by ELISA revealed a twofold elevated α-syn secretion in DNAJC5 WT overexpressing mDA compared to control with an empty vector in the presence of BaFA1 (Figure 7E). With both BaFA1 treatment and DNAJC5 overexpression, α-syn secretion was increased threefold (Figure 7E). We examined the cell lysate of mDA by immunoblot. The effect of BaFA1 inhibition was indicated by the appearance of a lipidated form of LC3 (LC3-II) (Figure 7F). BaFA1 treatment also induced more DNAJC5 oligomer formation (Figure 7F). We conclude that DNAJC5 stimulates α-syn secretion in differentiated DA neurons as it does in HEK293T cells.

The J domain and C-terminal tail (C tail) of DNAJC5 are dispensable for α-syn secretion

The secretion deficiency caused by the L115R mutation highlights the importance of the CS domain of DNAJC5 in regulating α-syn secretion. The structure of the J domain of DNAJC5 has been solved by nuclear magnetic resonance (NMR) (Patel et al., 2016). Recent progress in deep learning algorithms, exemplified by AlphaFold, enables atomic accuracy in protein structure prediction (Jumper et al., 2021). We searched the public AlphaFold database to examine the predicted structure of FL DNAJC5. In the predicted structure, the J domain showed a conserved overall globular J protein fold within the N-terminus, linked by the helical CS domain to the flexible C-terminal tail. Only a short helix was predicted to reside within the C-tail (Figure 8A). We refined the boundary of each domain in DNAJC5 based on the predicted structure.

Figure 8. Domain mapping of secretion-competent DNAJC5.

Figure 8.

(A) Predicted structure of DNAJC5 by AlphaFold. Color scheme: J domain (magenta), Cys string domain (yellow) and C-terminal helix (green). (B) DNAJC5 (ΔJ) was competent to induce α-syn secretion into the medium. HEK293T cells were transfected with indicated plasmids. Media were collected after 36 hr and evaluated with immunoblot. (C) DNAJC5 (ΔJ) formed oligomers in HEK293T cells. (D) Quantification of normalized α-syn secretion in HEK293T cells transfected with WT DNAJC5 or DNAJC5 (ΔJ). Quantification was based on immunoblot in (B) and (C). The α-syn secretion was calculated as the amount of α-syn in media divided by the amount in lysate. α-syn secretion in cells transfected with WT DNAJC5 was normalized as 1. (E) C-terminal truncated DNAJC5 constructs were competent to induce α-syn secretion in the medium. HEK293T cells were transfected with C-terminal truncated DNAJC5 and α-syn. DNAJC5 antibodies cannot recognize DNAJC5 (ΔC30) and DNAJC5 (ΔC40) because of a missing epitope in the C-terminus. Instead, DNAJC5 (ΔC30) and DNAJC5 (ΔC40) were detected by C-terminal FLAG tags. All the C-terminal truncated DNAJC5 constructs showed smear-like oligomers. (F) Expression of C-terminal truncated DNAJC5 constructs in HEK293T cells. Immunoblot of anti-FLAG antibody and anti-DNAJC5 antibody cross-validated the existence of oligomers. (G) Quantification of normalized α-syn secretion in HEK293T cells transfected with WT DNAJC5 or different C-terminal truncated DNAJC5 constructs (ΔC10, ΔC20, ΔC30, and ΔC40). Quantification was based on immunoblot in (E) and (F). The α-syn secretion was calculated as the amount of α-syn in media divided by the amount in lysate. α-syn secretion in cells without DNAJC5 transfection was normalized as 1.

Figure 8—source data 1. Uncropped immunoblot corresponding to Figure 8.

Using this information, we showed that oligomerization of DNAJC5 increased when the J domain was deleted (Figure 6—figure supplement 1A and Figure 8C). As recently reported by Lee et al., 2022, deletion of the J domain increased the level of α-syn secretion induced by DNAJC5 (Figure 8B and D). Next, we examined the function of the C-tail by truncating about 10 AAs at a time, resulting in a series of C-terminal truncated DNAJC5 constructs, that is, DNAJC5 ΔC10, ΔC20, ΔC30, and ΔC40. All four DNAJC5 C-terminal truncations were expressed and formed oligomers in cells (Figure 8F). C-terminal truncated oligomers were co-secreted with α-syn into the medium (Figure 8E and G). This result demonstrates that neither the J domain nor the C-tail is required for DNAJC5 to induce α-syn secretion.

Discussion

Transmission of protein aggregates and subsequent self-amplification is emerging as a common theme across various neurodegenerative diseases. DNAJC5 has been shown to control the release of neurodegenerative disease proteins but the mechanism of action of this protein in unconventional secretion remains elusive. In this study, we reconstituted DNAJC5-regulated α-syn secretion in cultured HEK293T cells, in RA neuronally differentiated human cells and in hiPSC-derived midbrain DA neurons. By combining this assay with medium and cellular fractionation, we demonstrated that membrane-anchoring of DNAJC5 through palmitoylation is crucial for its secretion and the secretion of α-syn as a soluble monomer. In addition, we observed the topological locations of DNAJC5 and α-syn within enlarged endosomes, presumably at an intermediate stage prior to secretion. Furthermore, DNAJC5 was found to form oligomers and the importance of the oligomerzation was highlighted by the use of a lipidated XPACK fusion peptide. Our findings on the role of DNAJC5 extend to differentiated DA neurons of human and mouse origin. Finally, we provide evidence that both palmitoylation and oligomerization are solely dependent on the CS domain, which is required for α-syn secretion. Based on our biochemical assays and imaging observations, we propose that palmitoylated DNAJC5 oligomers function at a step involving membrane translocation of cytosolic α-syn, enabling it to become competent for secretion (Figure 9).

Figure 9. A model for palmitoylated DNAJC5 oligomer-mediated α-syn secretion.

Figure 9.

(A) Recruitment of α-syn on the membrane by DNAJC5. DNAJC5 binds to α-syn and targets it to late endosomes by palmitoylation. DNAJC5 forms a high-order oligomer to accommodate α-syn. (B) Translocation of α-syn and DNAJC5 into the membrane compartment. Both α-syn and DNAJC5 are translocated into the endosome lumen along with intraluminal vesicles (ILVs), forming a multivesicular body (MVB). (C) Secretion of α-syn and DNAJC5. Upon fusion between MVB and plasma membrane (PM), the cargos are expelled into the extracellular space. α-syn is soluble. DNAJC5 exists in both soluble and membrane-bound forms. Further transmission potentially occurs after secretion.

The in vivo toxicity of α-syn aggregates remains elusive (Lashuel et al., 2013), but its propagation accompanies the progression of PD (Braak et al., 2006; Braak et al., 2003). Recently, Caló et al., 2021 found that DNAJC5 expression decreases in α-syn transgenic mice. Overexpression of DNAJC5 in vivo is reported to rescue α-syn aggregation-dependent pathology and increase the accumulation of monomeric α-syn (Caló et al., 2021). As we find and others have reported, iPSC-derived neurons also secrete α-syn in a largely soluble form (Fernandes et al., 2016). Using the criteria of differential sedimentation and gel filtration chromatography, we conclude that α-syn is secreted in cultures cells as a soluble monomeric species not enclosed within EVs, regardless of mutations modeled on PD (Figure 2—figure supplement 1A) or as expressed in tandem arrays or in gene fusions to tightly folded proteins (Figure 5—figure supplement 1). Consistent with our results, other MAPS substrates are also reported to be secreted in a soluble form (Lee et al., 2016). Although α-syn oligomers have also been found in EVs (Danzer et al., 2012; Emmanouilidou et al., 2010; Guo et al., 2020), we see no evidence for this in our culture medium fractionation and immunoblot experiments (Figure 2B). With a more sensitive and quantitative Nluc assay, 85% of secreted α-syn was found to be soluble (Figure 2—figure supplement 1B). Similarly, the basal level of α-syn secreted by differentiated neuroblastoma cells is mainly soluble and not detected within EVs (Figure 7—figure supplement 1A).

The release of soluble α-syn may be an early event in pathogenesis of PD, prior to the deposition of aggregates. Inhibition of the lysosomal ATPase with bafilomycin A (BaFA1) is known to induce lysosome fusion to the cell surface and secretion of lysosomal content including both soluble and aggregate forms of α-syn (Xie et al., 2022; Figure 1—figure supplement 3H, Figure 7E). Such secretion may be part of a cell protective mechanism but it may also promote the interneuronal spread of monomer and oligomer.

Numerous neuronal proteins are palmitoylated, including synaptic scaffolding proteins, signaling proteins, and synaptic vesicle proteins (Linder and Deschenes, 2007). Protein palmitoylation has been implicated in the pathogenesis of neurodegenerative diseases (Cho and Park, 2016). In PD particularly, a recent study reported that upregulation of cellular palmitoylation decreased α-syn cytoplasmic inclusions (Ho et al., 2021). The neuropathology and behavior deficiency of Huntington disease (HD) mice can be reversed by boosting brain palmitoylation (Virlogeux et al., 2021). In the case of DNAJC5, L115R, and L116Δ, the two adjacent mutations causing decreased palmitoylation of DNAJC5 monomers, lead to a familial form of NCL (Benitez et al., 2011; Diez-Ardanuy et al., 2017). Our results suggested that the secretion of neurodegenerative disease proteins is also dependent on palmitoylation, possibly alleviating the cellular burden of protein aggregate accumulation. Notably, the general inhibition of cellular palmitoylation by 2-BA led to a complete block of α-syn secretion, whereas the specific palmitoylation deficient DNAJC5 mutant L115R only partially decreased α-syn secretion (Figure 3). The difference implies the existence of palmitoylation-dependent factors other than DNAJC5.

Although DNAJC5 coexpressed with α-syn and palmitoylation are required for secretion, EV-associated P-DNAJC5 clearly separated from soluble α-syn in the culture medium (Figure 2B and Figure 2—figure supplement 2B). At which step do the two separate? In our live-cell imaging experiments, the internalized DNAJC5 inside enlarged endosomes had both punctate and diffuse distributions (Figure 4A). This may represent the soluble NP-DNAJC5 and membrane-attached P-DNAJC5, respectively. In the time-lapse imaging of internalized α-syn induced by DNAJC5, both DNAJC5 and α-syn moved dynamically inside the compartment, without significant colocalization (Figure 4—video 1). This observation suggests that the separation of DNAJC5 and α-syn may occur prior to their secretion when the late endosome and plasma membrane fuse.

Zhang et al., 2020 have reported a novel membrane channel, TMED10, for the unconventional secretion of IL-1β. These authors speculate an activation-on-demand oligomerization of TMED10 membrane subunits to form a conducting channel for substrate translocation, a process they refer to as THU (Zhang et al., 2020). α-syn was reported to not depend on TMED10 for unconventional secretion (Zhang et al., 2020). Similarly, in chaperone-mediated autophagy (CMA), cytosolic substrates are proposed to be translocated into lysosomes through a channel formed by the oligomerization of a single-transmembrane protein, LAMP2A (Bandyopadhyay et al., 2008). The secretion of α-syn has been shown to be independent of CMA (Lee et al., 2018). Without a transmembrane domain, membrane-tethered P-DNAJC5 oligomer is unlikely to be a channel for translocation. A recent report identified CD98hc, an AA transporter subunit, to be a DNAJC5 interactor that is required for α-syn secretion (Lee et al., 2022). It remains to be determined whether CD98hc or other as yet uncharacterized membrane proteins are directly involved in α-syn membrane translocation.

In SEC61-mediated co-translational translocation, substrates enter the SEC61 translocon in an unfolded state (Rapoport et al., 2017). In THU and CMA, substrate unfolding is also required for translocation across the membrane (Kaushik and Cuervo, 2018; Zhang et al., 2020). In striking contrast, unfolding and size is not a limiting factor for α-syn secretion (Figure 5). As a precedent of translocation without unfolding, studies have shown the import of folded proteins into the matrix of peroxisomes and obviously through the nuclear pore (Kim and Hettema, 2015; Lin and Hoelz, 2019). DNAJC5 forms a series of extremely stable oligomers, which may provide versatile adaptors to accommodate diverse misfolded or folded substrates with different dimensions. The structure of DNAJC5 oligomers may shed light on the principle of this folding-independent translocation pathway.

Materials and methods

Key resources table.

Reagent type (species) or resource Designation Source or reference Identifiers Additional information
Antibody Mouse monoclonal anti-α-synuclein BD Biosciences Cat# 610787 (1:500)
Antibody Rabbit polyclonal anti-α-synuclein Proteintech Cat# 10842-1-AP (1:500)
Antibody Rabbit polyclonal anti-DNAJC5 RayBiotech Cat# 144-10489-200 (1:1,000)
Antibody Mouse monoclonal anti-alpha tubulin Abcam Cat# ab7291 (1:2,000)
Antibody Mouse monoclonal anti-Alix Santa Cruz Biotechnology Cat# Sc-53540 (1:1,000)
Antibody Rabbit monoclonal anti-CD9 Cell Signaling Technology Cat# 13174S (1:1,000)
Antibody Mouse monoclonal anti-PDI Enzo Life Sciences Cat# ADI-SPA-891-D (1:1,000)
Antibody Mouse monoclonal anti-CD63 Thermo Fisher Scientific Cat# BDB556019 (1:1,000)
Antibody Mouse monoclonal anti-Flotillin-2 BD Biosciences Cat# 610383 (1:1,000)
Antibody Mouse monoclonal anti-Transferrin Receptor Thermo Fisher Scientific Cat# 13-6800 (1:1,000)
Antibody Mouse monoclonal anti-GM130 BD Biosciences Cat# 610823 (1:1,000)
Antibody Rabbit monoclonal anti-Tom20 Cell Signaling Technology Cat# 42406S (1:1,000)
Antibody Rabbit polyclonal anti-GFP Fisher Scientific Cat# NC9589665 (1:1,000)
Antibody Rabbit polyclonal anti-LC3B Novus Biologicals Cat# NB100-2220 (1:1,000)
Antibody Rabbit monoclonal anti-Citrate Synthase Cell Signaling Technology Cat# 14309S (1:1,000)
Antibody Rabbit polyclonal anti-Dopamine transporter Bioss Antibodies Cat# BS-1714R (1:1,000)
Antibody Rabbit monoclonal anti-beta III Tubulin Abcam Cat# ab215037 (1:1,000)
Antibody Rabbit polyclonal anti-Tyrosine hydroxylase Millipore Cat# AB152 (1:1,000)
Antibody Chicken polyclonal Microtubule-associated protein 2 Abcam Cat# ab92434 (1:1,000)
Antibody Mouse monoclonal anti-FLAG Sigma-Aldrich Cat# F9291 (1:1,000)
Strain, strain background (Escherichia coli) XL1-Blue competent cells MacroLab Berkeley N/A
Strain, strain background (E. coli) Rossetta (DE3) pLysS competent cells MacroLab Berkeley N/A
Chemical compound, drug Anti-FLAG M2 Affinity Gel Sigma-Aldrich Cat# A2220-5ML
Chemical compound, drug Dimethyl sulfoxide (DMSO) Thermo Fisher Scientific Cat# BP231-100
Chemical compound, drug Quercetin Sigma-Aldrich Cat# Q4951-10G
Chemical compound, drug 2-Bromopalmitic acid Millipore Sigma Cat# 21604-1G
Chemical compound, drug Balfilomycin A1 Cayman Chemical Cat# 11038
Chemical compound, drug Retinoic acid Sigma-Aldrich Cat# R2625-100MG
Chemical compound, drug HaloTag Oregon Green Ligand Promega Cat# G2802
Chemical compound, drug HaloTag TMR Ligand Promega Cat# G8251
Chemical compound, drug Prolong Gold with DAPI Thermo Fisher Scientific Cat# P36931
Chemical compound, drug Proteinase K Sigma-Aldrich Cat# P2308
Peptide, recombinant protein α-syn tandem repeats protein This paper N/A
Commercial assay or kit Nano-Glo Luciferase Assay System Promega Cat# N1150
Commercial assay or kit LEGEND MAX Human α-synuclein (Colorimetric) ELISA Kit BioLegend Cat# 448607
Commercial assay or kit Mouse α-synulcein ELISA Kit Abcam Cat# ab282865
Cell line (Homo sapiens) HEK293T cells Cell Culture Facility, UC Berkeley N/A
Cell line (H. sapiens) HEK293-lenti-X cells Cell Culture Facility, UC Berkeley N/A
Cell line (H. sapiens) MDA-MB-231 cells Cell Culture Facility, UC Berkeley N/A
Cell line (H. sapiens) Hela cells Cell Culture Facility, UC Berkeley N/A
Cell line (H. sapiens) SH-SY5Y cells Cell Culture Facility, UC Berkeley N/A
Cell line (H. sapiens) U2OS cells Cell Culture Facility, UC Berkeley N/A
Cell line (H. sapiens) HEK293T-DNAJC5-CRISPR KO cells This study N/A
Cell line (H. sapiens) SH-SY5Y-DNAJC5-shRNA KD cells This study N/A
Cell line (Mus musculus) Mouse Embryonic Stem Cells
Cell line (M. musculus) Mouse Embryonic Stem Cells-hDNAJC5-OE cells This study N/A
Cell line (H. sapiens) Human-Induced Pluripotent Stem Cells University of Oxford; EBiSC repository N/A
Recombinant DNA reagent mCherry-Rab5CA (Q79L) Addgene Cat# 35138
Recombinant DNA reagent BFP-Rab5CA (Q79L) This study N/A
Recombinant DNA reagent SNCA (Myc-DDK-tagged)-Human synuclein, alpha OriGene Technoogy Cat# RC221446
Recombinant DNA reagent CSP (DNAJC5) (NM_025219) Human Tagged ORF Clone OriGene Technology Cat# RC208826
Recombinant DNA reagent TCH1003-MGC premier cDNA clone for USP19 transOMIC Cat# TCH1003
Recombinant DNA reagent pCMV-α-synuclein-A30P Gift of Dr. Thomas Südhof lab N/A
Recombinant DNA reagent pCMV-α-synuclein-E46K Gift of Dr. Thomas Südhof lab N/A
Recombinant DNA reagent pCMV-α-synuclein-A53T Gift of Dr. Thomas Südhof lab N/A
Recombinant DNA reagent αS-2 (α-syn-α-syn) tandem dimer Gift of Michael Woodside lab N/A
Recombinant DNA reagent αS-4 (α-syn-α-syn-α-syn-α-syn) tandem Tetramer Gift of Michael Woodside lab N/A
Recombinant DNA reagent pCMV-αS-2 This study N/A
Recombinant DNA reagent pCMV-αS-4 This study N/A
Recombinant DNA reagent pCMV-DNAJC5-L115R This study N/A
Recombinant DNA reagent pCMV-DNAJC5-L116Δ This study N/A
Recombinant DNA reagent pCMV-DNAJC5 (WT)-HaloTag This study N/A
Recombinant DNA reagent pCMV-DNAJC5 (L115R)-HaloTag This study N/A
Recombinant DNA reagent pCMV-XPACK-DNAJC5 (L115R)-HaloTag This study N/A
Recombinant DNA reagent mNeonGreen-α-synuclein This study N/A
Recombinant DNA reagent 3H-α-synuclein This study N/A
Recombinant DNA reagent α-synuclein-3H This study N/A
Recombinant DNA reagent pCMV-XPACK-DNAJC5 (WT) This study N/A
Recombinant DNA reagent pCMV-XPACK-DNAJC5 (L115R) This study N/A
Recombinant DNA reagent pCMV-DEAD XPACK-DNAJC5 (L115R) This study N/A
Recombinant DNA reagent pCMV-DNAJC5-ΔJ (Δ14–82) This study N/A
Recombinant DNA reagent pCMV-DNAJC5-ΔC10 (D189–198) This study N/A
Recombinant DNA reagent pCMV-DNAJC5-ΔC20 (D179–198) This study N/A
Recombinant DNA reagent pCMV-DNAJC5-ΔC30 (D169–198) This study N/A
Recombinant DNA reagent pCMV-DNAJC5-ΔC40 (D151–198) This study N/A
Recombinant DNA reagent pCMV-pOTC-GFP This study N/A
Recombinant DNA reagent pCMV-pOTC-3H-GFP This study N/A
Recombinant DNA reagent pX330-Venus-DNAJC5-Exon 4-gRNA This study N/A
Recombinant DNA reagent pLenti-CMV-DNAJC5 This study N/A
Recombinant DNA reagent pLenti-CMV-DNAJC5 (L115R) This study N/A
Recombinant DNA reagent plKO.1-DNAJC5-ShRNA This study N/A
Software, algorithm Fiji (ImageJ) NIH https://imagej.nih.gov/ij/
Software, algorithm PyMOL Schrödinger https://pymol.org/2/
Software, algorithm Prism 8 Graphpad https://www.graphpad.com/scientific-software/prism/
Software, algorithm AlphaFold Protein Structure Database DeepMind https://alphafold.ebi.ac.uk/

Cell culture and transfection

All immortalized cell lines were obtained from the UC-Berkeley Cell Culture Facility and were confirmed by short tandem repeat (STR) profiling and tested negative for mycoplasma contamination. Cells were grown at 37°C in 5% CO2 and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). For secretion assays, the FBS concentration was reduced to 1% for up to 36 hr during which time the growth rate of cells slowed but cells remained viable. For EV preparation and medium fractionation, we grew cells in DMEM supplemented with exosome-depleted FBS. Exosome-depleted FBS was prepared by overnight centrifugation of 30% diluted FBS in DMEM at 100,000×g. Transfection of plasmids into cells was performed using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s protocols.

Reconstitution of α-syn secretion in HEK293T cells

HEK293T cells (cultured in six-well plates) were cultured to 60% confluence and co-transfected with plasmids encoding different constructs of α-syn and DNAJC5. pCMV-GFP was used as a transfection control in all secretion experiments. At 4 hr after transfection, we replaced cell culture medium with DMEM supplemented with 1% FBS containing indicated drugs for treatment. At indicated time points, we collected media fractions which were centrifuged at 1000×g for 10 min to remove floating cells and cell debris. The media were mixed with methanol/chloroform to precipitate proteins which were collected by centrifugation (10,000×g × 10 min) and resuspended in SDS-PAGE sample loading buffer to achieve concentration (20-fold). Cells were lysed in lysis buffer (10 mM Tris, pH 7.4, 100 mM NaCl, and 1% Triton X-100). Both the concentrated media and cell lysate fractions were analyzed by immunoblot.

To exclude the release of cytoplasmic proteins from cell death, we monitored the viability of cells after transfection with a Countess II Automated Cell Counter (Thermo Fisher Scientific) using trypan blue staining.

For a nanoluciferase-based assay, media fractions were collected and centrifuged at 1000×g for 10 min. The supernatant fractions were harvested and further diluted with PBS buffer (1000-fold). The nanoluciferase activity was assayed using a Nano-Glo Luciferase Assay System (Promega, Madison, WI) according to the manufacturer’s protocol.

Membrane and cytosol fractionation

Cells (one 10 cm dish) were cultured to 70% confluence and transfected with different constructs of DNAJC5. One day after transfection, we harvested the transfected cells by scraping in 1 ml B88 (20 mM HEPES-KOH, pH 7.2, 250 mM sorbitol, 150 mM potassium acetate, and 5 mM magnesium acetate) plus a cocktail of protease inhibitors (Sigma-Aldrich, St. Louis, MO). Cells were homogenized by 10 passages through a 22G needle. Homogenates were centrifuged at 500×g for 10 min and the resulting post-nuclear supernatant (PNS) fractions were centrifuged at 100,000×g for 1.5 hr. High-speed supernatant fractions were then subjected to a repeat centrifugation to achieve a clarified cytosol fraction. The pellet fraction was washed and resuspended in the same volume of B88. Resuspended material was also centrifuged again to collect a washed membrane fraction. Membranes were lysed in lysis buffer.

For membrane fractionation, the PNS was subjected to differential centrifugation at 3000×g (10 min), 25,000×g (20 min), and 100,000×g (30 min). Membrane fractions were normalized to phosphatidylcholine content and analyzed by immunoblot (Ge et al., 2013).

For proteinase K protection assays, the 25,000×g membrane fraction was aliquoted into three tubes: one without proteinase K, one with proteinase K (10 μg/ml), and one with proteinase K plus TritonX-100 (0.5%). The incubation was conducted on ice for 20 min and stopped by sequential addition of PMSF (1 mM) and sample buffer and samples were then heated on metal block at 95°C for 5 min and analyzed by SDS-PAGE and immunoblot.

In vitro depalmitoylation assay

Cells (HEK293T, MDA-MB-231, or Hela) were transfected with DNAJC5. Cellular membranes were prepared as described above. For chemical deplamitoylation, the membranes were resuspended and incubated with 0.5 M hydroxylamine (pH 7.2) or 0.5 M Tris (pH 7.2, control) at room temperature overnight in the presence of a cocktail of protease inhibitors (Sigma-Aldrich, St. Louis, MO). The mobility of DNAJC5 was examined by SDS-PAGE followed by immunoblot.

CRISPR/Cas9 genome editing

gRNA targeting exon 4 of DNAJC5 (CACCGGAGGCCGCAGAAGACAAACA) was inserted into a pX330-based plasmid expressing Venus fluorescent protein (Shurtleff et al., 2016). HEK293T cells were transfected with pX330-pX330-Venus-DNAJC5-Exon 4-gRNA by Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA). After 48 hr, we diluted the cells and single colonies were isolated, expanded, and determined for DNAJC5 KO by immunoblot.

Medium fractionation and EV preparation

Conditioned medium was harvested and centrifuged first at 1500×g for 20 min followed by 10,000×g for 30 min and 100,000×g for 1.5 hr. The supernatant fractions at each step were collected and treated with methanol/chloroform to precipitate proteins which were then collected by centrifugation. Pellet fractions were resuspended in sample buffer to achieve a 20-fold concentration. The sedimented fractions at each step were also collected and resuspended in sample buffer. All the fractions were analyzed by immunoblot.

EVs were isolated by buoyant density flotation on a sucrose step gradient. The pellet fraction from a 100,000×g centrifugation was resuspended in PBS and mixed with 60% sucrose buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl) to achieve a final sucrose concentration >50% as measured with a refractometer. Aliquots of 40% (5 ml) and 10% (2 ml) sucrose buffer were sequentially overlaid above the sample. The tubes were then centrifuged at 150,000×g for 16 hr in an SW41 Ti swinging-bucket rotor (Beckman Coulter). After centrifugation, 0.5 ml fractions were collected from top to bottom and samples were analyzed by SDS-PAGE and immunoblot.

Co-immunoprecipitation

Media fractions were collected and centrifuged at 1000×g for 10 min. The supernatant fractions were collected and concentrated (20-fold) using a 10 kDa Amicon filter (Millipore, Billerica, MA). Concentrated media fractions (1 ml) were incubated with 20 μl of anti-FLAG M2 affinity gel (Sigma-Aldrich, St. Louis, MO) for 1 hr at 4°C. After washing 5× with lysis buffer, SDS-PAGE sample loading buffer was added to the beads and samples were processed for SDS-PAGE and immunoblot.

Protein purification

The purification of different α-syn tandem-oligomer constructs was performed as previously described (Dong et al., 2018). Briefly, an osmotic shock protocol was adapted to enrich proteins released from the periplasm of transfected Escherichia coli. The supernatant fraction containing released proteins was subjected to ammonium sulfate (AS) precipitation, with 50%, 45%, and 40% saturated concentration of AS for monomer, dimer, and tetramer, respectively. After overnight precipitation, the precipitated proteins were collected by centrifugation at 100,000×g for 30 min. The pellet fractions were dissolved in Buffer A (20 mM Tris-HCl pH 8.0) and clarified by repeated centrifugation at 100,000×g for 30 min.

Clarified supernatants were applied to an equilibrated HiPrep Q Fast Flow 16/10 column (GE Healthcare, Chicago, IL). Eluted proteins were collected, concentrated by 10 kDa Amicon filter (Millipore, Billerica, MA) and further purified by gel filtration (Superdex-200, GE Healthcare) with PBS used as gel filtration buffer. Purified proteins were assessed by SDS-PAGE followed by coomassie-blue staining.

IF and live-cell Imaging

For IF, U2OS cells were washed once with PBS and immediately fixed by 4% EM-grade paraformaldehyde (Electron Microscopy Science, Hatfield, PA) for 10 min at room temperature. Cells were washed three times with PBS and blocked and permeabilized for 30 min in permeabilization buffer (5% FBS and 0.1% saponin in PBS). hiPSC dopamine neurons were fixed with 4% paraformaldehyde in PBS and 0.1% Triton-X was used for permablization (10 min) followed by blocking in 10% normal donkey serum for 1 hr. Cells were then incubated with 1:100 dilution of primary antibodies overnight at 4°C. After three washes with PBS, cells were incubated with 1:500 dilution of fluorophore-conjugated secondary antibodies for 30 min at room temperature. Prolong Gold with DAPI (Thermo Fisher Scientific) was used as mounting solution. Images were acquired with a Zeiss LSM900 confocal microscope and analyzed with Fiji/ImageJ software (https://imagej.nih.gov/ij/).

For live-cell imaging, cells were cultured in 35 mm glass bottom dishes (MatTek). The addition of HaloTag fluorescent ligands were added according to the manufacturer’s protocol (Promega). After incubation, the medium was replaced with Opti-MEM supplemented with 10% FBS. Imaging was performed using a Zeiss LSM900 confocal microscope in a temperature-controlled (37°C and 5% CO2) environment.

Mitochondria purification

HEK293T cells were trypsinized and collected by centrifugation. Cells were washed twice with NKM buffer (1 mM Tris HCl, pH7.3, 0.13 M NaCl, 5 mM KCl, and 7.5 mM MgCl2), and resuspended in six packed cell volumes of homogenization buffer (10 mM Tris pH 7.4, 10 mM KCl, and 0.15 mM MgCl2). Cells were homogenized by 10 passages through a 22G needle. Cell homogenates were mixed gently with the same volume of 2.3 M sucrose solution and centrifuged at 1200×g for 5 min to remove unbroken cells and large cell debris. The recovered supernatant fractions were centrifuged at 7000×g for 10 min. Mitochondria enriched in the pellet fraction were resuspended in three packed cell volumes of Mitochondria Suspension Buffer (10 mM Tris, pH 7.3, 0.15 mM MgCl2, and 0.25 mM sucrose).

Differentiation of SH-SY5Y cells

SH-SY5Y neuroblastoma cells were maintained in DMEM supplemented with 1× nonessential amino acid (NEAA), 1× sodium pyruvate, and 10% FBS. Differentiation was induced by lowering the FBS in culture medium to 1% plus 10 μM RA. Cell medium was replaced each 3 days to replenish RA. Cell morphology was monitored by microscopy and experiments on SH-SY5Y cells were performed from D6 of differentiation.

shRNA knockdown

plKO.1-Hygro plasmids-containing shRNA targeting DNAJC5 (ccggGCAACCTCAGATGACATTAAACTCGAGTTTAATGTCATCTGAGGTTGCTTTTTG) together with pMD2.G and PsPAX2 were transfected into HEK293T cells to produce lentiviral particles for 72 hr. Lentivirus particles were concentrated with Lenti-X Concentrator (Takara Bio). SH-SY5Y was transduced by lentivirus before differentiation. Three days post transduction, cells were selected with 250 μg/ml hygromycin for 10 days. The selected cells were differentiated, and the knockdown was verified with immunoblot.

Culture and differentiation of mESCs

Mouse ESCs (R1) were maintained and differentiated into dopaminergic neurons following a modified protocol from Ni et al., 2013. Briefly, R1 cells were maintained in a feeder-independent system, plated in 0.1% gelatin (StemCell Technologies) and cultured in KSR medium consisting of KnockOut DMEM, 20% KnockOut serum replacement, 2 mM L-glutamine, 0.1 mM NEAAs, 0.1 mM β-mercaptoethanol, and 1000 U/ml leukemia inhibitory factor (LIF, Chemicon International) with a media change every day. Cells were then grown in aggregate cultures to form EBs in DMEM/F12 media supplemented with 10% knockout serum replacement, 2.4% N2, 4500 mg/L Glucose, 2 mM L-glutamine, and 0.1 mM β-mercaptoethanol. EBs were formed for 4 days and then plated on 10 µg/ml laminin-coated plates. After 24 hr of culture, the media were replaced by DMEM/F12, 3% KO serum, N2, Glucose, 1× Glutamine, and 2-BME supplemented with 1% Insulin/Transferrin/Selenium with a media change every day. After 7 days, cells were dissociated by Accutase StemPro and plated on laminin-coated plates using a 1:1 ratio of Neurobasal media and DMEM/F12, N2, B27, 2 mM L-glutamine, 0.1 mM NEAAs, 0.1 mM β-mercaptoethanol supplemented with 20 ng/ml bFGF (R&D Systems), 200 ng/ml SHH (R&D Systems), and 25 ng/ml FGF8b (R&D Systems) with a media change every day. After 8 days, the culture medium was changed to Neurobasal/B27 medium supplemented with 0.5 mM dbcAMP (Santa Cruz Biotechnology), 0.2 mM ascorbic acid (StemCell Technologies), 20 ng/ml BDNF (Petrotech), and 20 ng/ml GDNF (Petrotech) with a media change every other day.

Differentiation and culture of dopaminergic neurons from hiPSCs

Primary fibroblasts derived from PD patients carrying the GBA-N370S mutation and a healthy control (below) were reprogrammed to pluripotency as described previously (Fernandes et al., 2016) and clones were selected, tested for mycoplasma and QCed according to established protocols (Lang et al., 2019). hiPSCs were differentiated toward dopaminergic fate as described by Kriks et al., 2011 with small modifications (Beevers et al., 2017). Briefly, hiPSCs were patterned for 21 days with a growth factor cocktail to promote differentiation toward ventral midbrain neuronal progenitor cells for 11 days (10 mM SB431542, Tocris; 100 nM LDN193189, Sigma-Aldrich; 2 mM puromorphamine, Millipore; 100 ng/ml sonic hedgehog, Bio-Techne; 100 ng/ml fibroblast growth factor-8a, Bio-Techne, and 3 mM CHIR99021), followed by 10 days of differentiation to dopaminergic neurons (20 ng/ml brain-derived neurotrophic factor, Peprotech; 20 ng/ml glial cell line-derived neurotrophic factor, Peprotech; 1 ng/ml transforming growth factor type β3, Peprotech; 0.5 mM dibutyryl cAMP, Sigma-Aldrich; 0.2 mM Ascorbic acid, Sigma-Aldrich, and 10 mM DAPT, Abcam). Neurons were matured for a further 2 weeks (to day 35) for α-synuclein secretion, or for a further 5 weeks (to day 65) for analysis by SDS-PAGE and immunoblot. Neurons were then treated with DMSO, quercetin, or 2-bromoplamitic acid for 3 days.

Donor ID Study ID Genotype Age/gender Characterization
SFC156-03 Control GBA wt/GBA wt 75 Male Lang et al., 2019
MK071 PD 1 GBA N370S/GBA wt 81 Female Fernandes et al., 2016
MK088 PD 2 GBA N370S/GBA wt 46 Male Fernandes et al., 2016
SFC871-03-09 PD 3 GBA N370S/GBA wt 70 Female Bogetofte et al., 2021
MK082 PD 4 GBA N370S/GBA wt 51 Male Lang et al., 2019

Extracellular α-syn measurements

Commercial ELISA Kits as listed in Key Resources Table were used to quantify the extracellular α-syn in SH-SY5Y and mouse mDA neuronal culture. Conditioned media were collected and centrifuged at 1000×g for 10 min. α-syn in the recovered supernatant was measured using the protocol provided in the kit.

α-syn secretion by hiPSC-derived dopaminergic neurons was measured as described previously (Fernandes et al., 2016; Fernandes et al., 2016) using an electro-chemiluminescent assay (Meso Scale Discovery, MD, Cat# K151TGD-2) and a MESO QuickPlex SQ 120 instrument (Meso Scale Discovery) according to the manufacturer’s instructions. Briefly, culture media were collected 3 days after drug treatment (differentiation day 38) and quantified relative to a standard curve. Data were normalized relative to the total protein content of the cells from which the conditioned media had been collected, as determined by BCA assay.

Immunoblots

Cell lysate, cytosol, or membrane samples, and EV samples were mixed with SDS sample loading buffer. Samples were heated at 95°C for 5 min and separated on SDS-PAGE gels. Proteins were transferred to PVDF membranes (EMD Millipore, Darmstadt, Germany), blocked with 5% bovine serum albumin in TBST (20 mM Tris pH 7.4, 150 mM NaCl, and 0.1% Tween-20) and incubated overnight with primary antibodies. For immunoblots from hiPSC dopamine neurons, samples in loading buffer were heated to 70°C for 10 min and blocking was carried out with 5% skimmed milk. For immunoblots of endogenous α-syn in SH-SY5Y cells, PVDF membranes were fixed with 0.4% paraformaldehyde (Electron Microscopy Science, Hatfield, PA) in TBST at room temperature for 30 min (Lee and Kamitani, 2011). Blots were then washed with TBST, followed by incubation with anti-rabbit or anti-mouse secondary antibodies (GE Healthcare Life Sciences, Pittsburgh, PA). Detection was performed with Supersignal Chemiluminescent substrate (Thermo Fisher Scientific) and quantified with Fiji/ImageJ. Primary antibodies used in this study were listed in Key Resources Table. All antibodies used for immunoblots were diluted 1:1000, except for 1:2000 of mouse anti-Tubulin, 1:500 of rabbit anti-α-syn and of rabbit anti-tyrosine hydroxylase.

Acknowledgements

The authors thank Dr. Michael Woodside and Dr. Thomas Südhof for sharing the plasmids, and Dr. Kalina Naidoo, Dr. Mootaz Salman and William McGuinness for preparation of iPSC samples. The authors also thank the staff at the UC Berkeley Shared Facilities, the Cell Culture Facility, the DNA Sequencing Facility, and the Biological Imaging Facility. SW is supported as Associate of the HHMI. RS is an Investigator of the HHMI, a senior fellow of the UC Berkeley Miller Institute of Science and the Scientific Director of Aligning Science across Parkinson’s disease.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Randy Schekman, Email: schekman@berkeley.edu.

Suzanne R Pfeffer, Stanford University, United States.

Suzanne R Pfeffer, Stanford University, United States.

Funding Information

This paper was supported by the following grants:

  • Howard Hughes Medical Institute to Randy Schekman.

  • NIH Biology and Biotechnology of Cell and Gene Therapy Training Program NIH training program T32GM139780 to Nancy C Hernandez Villegas.

  • Aligning Science Across Parkinson's ASAP-020370 to Richard Wade-Martins, Randy Schekman.

Additional information

Competing interests

No competing interests declared.

Reviewing editor, eLife.

Author contributions

Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing.

Formal analysis, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing.

Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing.

Formal analysis, Investigation, Writing - original draft, Writing - review and editing.

Formal analysis, Funding acquisition, Writing - original draft, Writing - review and editing.

Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Writing - review and editing.

Additional files

MDAR checklist

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for all the Figures.

References

  1. Abounit S, Bousset L, Loria F, Zhu S, de Chaumont F, Pieri L, Olivo-Marin J-C, Melki R, Zurzolo C. Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes. The EMBO Journal. 2016;35:2120–2138. doi: 10.15252/embj.201593411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alderson TR, Markley JL. Biophysical characterization of α-synuclein and its controversial structure. Intrinsically Disordered Proteins. 2013;1:18–39. doi: 10.4161/idp.26255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM. The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Molecular and Cellular Biology. 2008;28:5747–5763. doi: 10.1128/MCB.02070-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beevers JE, Lai MC, Collins E, Booth HDE, Zambon F, Parkkinen L, Vowles J, Cowley SA, Wade-Martins R, Caffrey TM. MAPT genetic variation and neuronal maturity alter isoform expression affecting axonal transport in ipsc-derived dopamine neurons. Stem Cell Reports. 2017;9:587–599. doi: 10.1016/j.stemcr.2017.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benitez BA, Alvarado D, Cai Y, Mayo K, Chakraverty S, Norton J, Morris JC, Sands MS, Goate A, Cruchaga C. Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLOS ONE. 2011;6:e26741. doi: 10.1371/journal.pone.0026741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bogetofte H, Ryan BJ, Jensen P, Vergoossen DLE, Barnkob MB, Kiani L, Chughtai U, Brandes J, Vowles J, Bunn F, Kilfeather P, Fernandes HJR, Caffrey T, Meyer M, Cowley SA, Larsen MR, Wade-Martins R. A Novel Post-Translational Proteomics Platform Identifies Neurite Outgrowth Impairments in Parkinson’s Disease GBA-N370S Dopamine Neurons. bioRxiv. 2021 doi: 10.1101/2021.06.30.450333. [DOI] [PubMed]
  7. Bohdanowicz M, Balkin DM, De Camilli P, Grinstein S. Recruitment of OCRL and Inpp5b to phagosomes by Rab5 and APPL1 depletes phosphoinositides and attenuates Akt signaling. Molecular Biology of the Cell. 2012;23:176–187. doi: 10.1091/mbc.E11-06-0489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, Abbruzzese G, Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neuroscience Letters. 2000;287:65–67. doi: 10.1016/s0304-3940(00)01153-8. [DOI] [PubMed] [Google Scholar]
  9. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24:197–211. doi: 10.1016/s0197-4580(02)00065-9. [DOI] [PubMed] [Google Scholar]
  10. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neuroscience Letters. 2006;396:67–72. doi: 10.1016/j.neulet.2005.11.012. [DOI] [PubMed] [Google Scholar]
  11. Brahic M, Bousset L, Bieri G, Melki R, Gitler AD. Axonal transport and secretion of fibrillar forms of α-synuclein, Aβ42 peptide and httexon 1. Acta Neuropathologica. 2016;131:539–548. doi: 10.1007/s00401-016-1538-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Buratta S, Tancini B, Sagini K, Delo F, Chiaradia E, Urbanelli L, Emiliani C. Lysosomal exocytosis, exosome release and secretory autophagy: the autophagic- and endo-lysosomal systems go extracellular. International Journal of Molecular Sciences. 2020;21:2576. doi: 10.3390/ijms21072576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Burré J, Sharma M, Südhof TC. Α-synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. PNAS. 2014;111:E4274–E4283. doi: 10.1073/pnas.1416598111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Caló L, Hidari E, Wegrzynowicz M, Dalley JW, Schneider BL, Podgajna M, Anichtchik O, Carlson E, Klenerman D, Spillantini MG. Cspα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice. Brain. 2021;144:1661–1669. doi: 10.1093/brain/awab076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cashikar AG, Hanson PI. A cell-based assay for CD63-containing extracellular vesicles. PLOS ONE. 2019;14:e0220007. doi: 10.1371/journal.pone.0220007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. Alpha-Synuclein cooperates with cspalpha in preventing neurodegeneration. Cell. 2005;123:383–396. doi: 10.1016/j.cell.2005.09.028. [DOI] [PubMed] [Google Scholar]
  17. Cho E, Park M. Palmitoylation in Alzheimer’s disease and other neurodegenerative diseases. Pharmacological Research. 2016;111:133–151. doi: 10.1016/j.phrs.2016.06.008. [DOI] [PubMed] [Google Scholar]
  18. Chu Y, Muller S, Tavares A, Barret O, Alagille D, Seibyl J, Tamagnan G, Marek K, Luk KC, Trojanowski JQ, Lee VMY, Kordower JH. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019;142:3565–3579. doi: 10.1093/brain/awz296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chung HK, Ho H-A, Pérez-Acuña D, Lee S-J. Modeling α-synuclein propagation with preformed fibril injections. Journal of Movement Disorders. 2020;13:77–79. doi: 10.14802/jmd.19046.e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular Neurodegeneration. 2012;7:42. doi: 10.1186/1750-1326-7-42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909. doi: 10.1016/s0896-6273(03)00568-3. [DOI] [PubMed] [Google Scholar]
  22. Deng J, Koutras C, Donnelier J, Alshehri M, Fotouhi M, Girard M, Casha S, McPherson PS, Robbins SM, Braun JEA. Neurons export extracellular vesicles enriched in cysteine string protein and misfolded protein cargo. Scientific Reports. 2017;7:956. doi: 10.1038/s41598-017-01115-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Deruelle V, Bouillot S, Job V, Taillebourg E, Fauvarque MO, Attrée I, Huber P. The bacterial toxin exou requires a host trafficking chaperone for transportation and to induce necrosis. Nature Communications. 2021;12:4024. doi: 10.1038/s41467-021-24337-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Diez-Ardanuy C, Greaves J, Munro KR, Tomkinson NCO, Chamberlain LH. A cluster of palmitoylated cysteines are essential for aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis. Scientific Reports. 2017;7:10. doi: 10.1038/s41598-017-00036-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dong C, Hoffmann M, Li X, Wang M, Garen CR, Petersen NO, Woodside MT. Structural characteristics and membrane interactions of tandem α-synuclein oligomers. Scientific Reports. 2018;8:6755. doi: 10.1038/s41598-018-25133-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. El-Agnaf OMA, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DMA, Ikeda S, Cookson MR, Hardy J, Allsop D. Alpha-Synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB Journal. 2003;17:1945–1947. doi: 10.1096/fj.03-0098fje. [DOI] [PubMed] [Google Scholar]
  27. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-Produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. The Journal of Neuroscience. 2010;30:6838–6851. doi: 10.1523/JNEUROSCI.5699-09.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. England CG, Ehlerding EB, Cai W. Nanoluc: a small luciferase is brightening up the field of bioluminescence. Bioconjugate Chemistry. 2016;27:1175–1187. doi: 10.1021/acs.bioconjchem.6b00112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fernandes HJR, Hartfield EM, Christian HC, Emmanoulidou E, Zheng Y, Booth H, Bogetofte H, Lang C, Ryan BJ, Sardi SP, Badger J, Vowles J, Evetts S, Tofaris GK, Vekrellis K, Talbot K, Hu MT, James W, Cowley SA, Wade-Martins R. Er stress and autophagic perturbations lead to elevated extracellular α-synuclein in GBA-N370S Parkinson’s iPSC-derived dopamine neurons. Stem Cell Reports. 2016;6:342–356. doi: 10.1016/j.stemcr.2016.01.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Fontaine SN, Zheng D, Sabbagh JJ, Martin MD, Chaput D, Darling A, Trotter JH, Stothert AR, Nordhues BA, Lussier A, Baker J, Shelton L, Kahn M, Blair LJ, Stevens SM, Jr, Dickey CA. DnaJ/hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins. The EMBO Journal. 2016;35:1537–1549. doi: 10.15252/embj.201593489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Førland MG, Öhrfelt A, Dalen I, Tysnes O-B, Blennow K, Zetterberg H, Pedersen KF, Alves G, Lange J. Evolution of cerebrospinal fluid total α-synuclein in Parkinson’s disease. Parkinsonism & Related Disorders. 2018;49:4–8. doi: 10.1016/j.parkreldis.2018.01.018. [DOI] [PubMed] [Google Scholar]
  32. Ge L, Melville D, Zhang M, Schekman R. The ER-Golgi intermediate compartment is a key membrane source for the LC3 lipidation step of autophagosome biogenesis. eLife. 2013;2:e00947. doi: 10.7554/eLife.00947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Greaves J, Chamberlain LH. Dual role of the cysteine-string domain in membrane binding and palmitoylation-dependent sorting of the molecular chaperone cysteine-string protein. Molecular Biology of the Cell. 2006;17:4748–4759. doi: 10.1091/mbc.e06-03-0183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Greaves J, Salaun C, Fukata Y, Fukata M, Chamberlain LH. Palmitoylation and membrane interactions of the neuroprotective chaperone cysteine-string protein. The Journal of Biological Chemistry. 2008;283:25014–25026. doi: 10.1074/jbc.M802140200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Greaves J, Lemonidis K, Gorleku OA, Cruchaga C, Grefen C, Chamberlain LH. Palmitoylation-induced aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis. The Journal of Biological Chemistry. 2012;287:37330–37339. doi: 10.1074/jbc.M112.389098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Guerrero-Ferreira R., Taylor NM, Mona D, Ringler P, Lauer ME, Riek R, Britschgi M, Stahlberg H. Cryo-Em structure of alpha-synuclein fibrils. eLife. 2018;7:e36402. doi: 10.7554/eLife.36402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Guerrero-Ferreira R, Taylor NM, Arteni AA, Kumari P, Mona D, Ringler P, Britschgi M, Lauer ME, Makky A, Verasdonck J, Riek R, Melki R, Meier BH, Böckmann A, Bousset L, Stahlberg H. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. eLife. 2019;8:e48907. doi: 10.7554/eLife.48907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Guo M, Wang J, Zhao Y, Feng Y, Han S, Dong Q, Cui M, Tieu K. Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease. Brain. 2020;143:1476–1497. doi: 10.1093/brain/awaa090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Hikita T, Miyata M, Watanabe R, Oneyama C. Sensitive and rapid quantification of exosomes by fusing luciferase to exosome marker proteins. Scientific Reports. 2018;8:14035. doi: 10.1038/s41598-018-32535-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ho GPH, Ramalingam N, Imberdis T, Wilkie EC, Dettmer U, Selkoe DJ. Upregulation of cellular palmitoylation mitigates α-synuclein accumulation and neurotoxicity. Movement Disorders. 2021;36:348–359. doi: 10.1002/mds.28346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Horwich AL, Kalousek F, Mellman I, Rosenberg LE. A leader peptide is sufficient to direct mitochondrial import of a chimeric protein. The EMBO Journal. 1985;4:1129–1135. doi: 10.1002/j.1460-2075.1985.tb03750.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Huang PS, Oberdorfer G, Xu C, Pei XY, Nannenga BL, Rogers JM, DiMaio F, Gonen T, Luisi B, Baker D. High thermodynamic stability of parametrically designed helical bundles. Science. 2014;346:481–485. doi: 10.1126/science.1257481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-Classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. Journal of Neurochemistry. 2010;113:1263–1274. doi: 10.1111/j.1471-4159.2010.06695.x. [DOI] [PubMed] [Google Scholar]
  44. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D. Highly accurate protein structure prediction with alphafold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nature Reviews. Molecular Cell Biology. 2018;19:365–381. doi: 10.1038/s41580-018-0001-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Kim PK, Hettema EH. Multiple pathways for protein transport to peroxisomes. Journal of Molecular Biology. 2015;427:1176–1190. doi: 10.1016/j.jmb.2015.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Kim S, Kwon S-H, Kam T-I, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, Pasricha PJ, Lee G, Pomper MG, Dawson VL, Dawson TM, Ko HS. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103:627–641. doi: 10.1016/j.neuron.2019.05.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nature Medicine. 2008;14:504–506. doi: 10.1038/nm1747. [DOI] [PubMed] [Google Scholar]
  49. Kriks S, Shim J-W, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature. 2011;480:547–551. doi: 10.1038/nature10648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Kuhlman B, Bradley P. Advances in protein structure prediction and design. Nature Reviews. Molecular Cell Biology. 2019;20:681–697. doi: 10.1038/s41580-019-0163-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Lang C, Campbell KR, Ryan BJ, Carling P, Attar M, Vowles J, Perestenko OV, Bowden R, Baig F, Kasten M, Hu MT, Cowley SA, Webber C, Wade-Martins R. Single-cell sequencing of ipsc-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of parkinson cell phenotypes. Stem Cell. 2019;24:93–106. doi: 10.1016/j.stem.2018.10.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. Alpha-Synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. Journal of Molecular Biology. 2002;322:1089–1102. doi: 10.1016/s0022-2836(02)00735-0. [DOI] [PubMed] [Google Scholar]
  53. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nature Reviews. Neuroscience. 2013;14:38–48. doi: 10.1038/nrn3406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. The Journal of Neuroscience. 2005;25:6016–6024. doi: 10.1523/JNEUROSCI.0692-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Lee BR, Kamitani T. Improved immunodetection of endogenous α-synuclein. PLOS ONE. 2011;6:e23939. doi: 10.1371/journal.pone.0023939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Lee JG, Takahama S, Zhang G, Tomarev SI, Ye Y. Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nature Cell Biology. 2016;18:765–776. doi: 10.1038/ncb3372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Lee J, Xu Y, Zhang T, Cui L, Saidi L, Ye Y. Secretion of misfolded cytosolic proteins from mammalian cells is independent of chaperone-mediated autophagy. The Journal of Biological Chemistry. 2018;293:14359–14370. doi: 10.1074/jbc.RA118.003660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Lee J, Xu Y, Saidi L, Xu M, Zinsmaier K, Ye Y. Abnormal triaging of misfolded proteins by adult neuronal ceroid lipofuscinosis-associated DNAJC5/cspα mutants causes lipofuscin accumulation. Autophagy. 2022;19:204–223. doi: 10.1080/15548627.2022.2065618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Li J-Y, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nature Medicine. 2008;14:501–503. doi: 10.1038/nm1746. [DOI] [PubMed] [Google Scholar]
  60. Lin DH, Hoelz A. The structure of the nuclear pore complex (an update) Annual Review of Biochemistry. 2019;88:725–783. doi: 10.1146/annurev-biochem-062917-011901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. Nature Reviews. Molecular Cell Biology. 2007;8:74–84. doi: 10.1038/nrm2084. [DOI] [PubMed] [Google Scholar]
  62. Lopes FM, Schröder R, da Frota MLC, Zanotto-Filho A, Müller CB, Pires AS, Meurer RT, Colpo GD, Gelain DP, Kapczinski F, Moreira JCF, Fernandes MDC, Klamt F. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for parkinson disease studies. Brain Research. 2010;1337:85–94. doi: 10.1016/j.brainres.2010.03.102. [DOI] [PubMed] [Google Scholar]
  63. Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, Zimprich C, Wood MG, Learish R, Ohana RF, Urh M, Simpson D, Mendez J, Zimmerman K, Otto P, Vidugiris G, Zhu J, Darzins A, Klaubert DH, Bulleit RF, Wood KV. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chemical Biology. 2008;3:373–382. doi: 10.1021/cb800025k. [DOI] [PubMed] [Google Scholar]
  64. Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM-Y. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949–953. doi: 10.1126/science.1227157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Neupert W. Protein import into mitochondria. Annual Review of Biochemistry. 1997;66:863–917. doi: 10.1146/annurev.biochem.66.1.863. [DOI] [PubMed] [Google Scholar]
  66. Ni N, Hu Y, Ren H, Luo C, Li P, Wan JB, Su H. Self-Assembling peptide nanofiber scaffolds enhance dopaminergic differentiation of mouse pluripotent stem cells in 3-dimensional culture. PLOS ONE. 2013;8:e84504. doi: 10.1371/journal.pone.0084504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Nosková L, Stránecký V, Hartmannová H, Přistoupilová A, Barešová V, Ivánek R, Hůlková H, Jahnová H, van der Zee J, Staropoli JF, Sims KB, Tyynelä J, Van Broeckhoven C, Nijssen PCG, Mole SE, Elleder M, Kmoch S. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. American Journal of Human Genetics. 2011;89:241–252. doi: 10.1016/j.ajhg.2011.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Patel P, Prescott GR, Burgoyne RD, Lian LY, Morgan A. Phosphorylation of cysteine string protein triggers a major conformational switch. Structure. 2016;24:1380–1386. doi: 10.1016/j.str.2016.06.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Rapoport TA, Li L, Park E. Structural and mechanistic insights into protein translocation. Annual Review of Cell and Developmental Biology. 2017;33:369–390. doi: 10.1146/annurev-cellbio-100616-060439. [DOI] [PubMed] [Google Scholar]
  70. Resh MD. Use of analogs and inhibitors to study the functional significance of protein palmitoylation. Methods. 2006;40:191–197. doi: 10.1016/j.ymeth.2006.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Scheiblich H, Dansokho C, Mercan D, Schmidt SV, Bousset L, Wischhof L, Eikens F, Odainic A, Spitzer J, Griep A, Schwartz S, Bano D, Latz E, Melki R, Heneka MT. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184:5089–5106. doi: 10.1016/j.cell.2021.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Castaño-Díez D, Schweighauser G, Graff-Meyer A, Goldie KN, Sütterlin R, Huisman E, Ingrassia A, Gier Y de, Rozemuller AJM, Wang J, Paepe AD, Erny J, Staempfli A, Hoernschemeyer J, Großerüschkamp F, Niedieker D, El-Mashtoly SF, Quadri M, Van IJcken WFJ, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, Van de Berg WDJ, Lauer ME. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nature Neuroscience. 2019;22:1099–1109. doi: 10.1038/s41593-019-0423-2. [DOI] [PubMed] [Google Scholar]
  73. Shurtleff MJ, Temoche-Diaz MM, Karfilis KV, Ri S, Schekman R. Y-Box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. eLife. 2016;5:e19276. doi: 10.7554/eLife.19276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Stefanis L. Α-Synuclein in Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2:a009399. doi: 10.1101/cshperspect.a009399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Strohäker T, Jung BC, Liou SH, Fernandez CO, Riedel D, Becker S, Halliday GM, Bennati M, Kim WS, Lee SJ, Zweckstetter M. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nature Communications. 2019;10:5535. doi: 10.1038/s41467-019-13564-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Stykel MG, Humphries KM, Kamski-Hennekam E, Buchner-Duby B, Porte-Trachsel N, Ryan T, Coackley CL, Bamm VV, Harauz G, Ryan SD. Α-synuclein mutation impairs processing of endomembrane compartments and promotes exocytosis and seeding of α-synuclein pathology. Cell Reports. 2021;35:109099. doi: 10.1016/j.celrep.2021.109099. [DOI] [PubMed] [Google Scholar]
  77. Tapper H, Sundler R. Bafilomycin A1 inhibits lysosomal, phagosomal, and plasma membrane H (+) -ATPase and induces lysosomal enzyme secretion in macrophages. Journal of Cellular Physiology. 1995;163:137–144. doi: 10.1002/jcp.1041630116. [DOI] [PubMed] [Google Scholar]
  78. Virlogeux A, Scaramuzzino C, Lenoir S, Carpentier R, Louessard M, Genoux A, Lino P, Hinckelmann M-V, Perrier AL, Humbert S, Saudou F. Increasing brain palmitoylation rescues behavior and neuropathology in Huntington disease mice. Science Advances. 2021;7:eabb0799. doi: 10.1126/sciadv.abb0799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Xie YX, Naseri NN, Fels J, Kharel P, Na Y, Lane D, Burré J, Sharma M. Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models. Nature Communications. 2022;13:4918. doi: 10.1038/s41467-022-32625-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Xu Y, Cui L, Dibello A, Wang L, Lee J, Saidi L, Lee JG, Ye Y. Dnajc5 facilitates USP19-dependent unconventional secretion of misfolded cytosolic proteins. Cell Discovery. 2018;4:11. doi: 10.1038/s41421-018-0012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Yano M, Kanazawa M, Terada K, Namchai C, Yamaizumi M, Hanson B, Hoogenraad N, Mori M. Visualization of mitochondrial protein import in cultured mammalian cells with green fluorescent protein and effects of overexpression of the human import receptor Tom20. The Journal of Biological Chemistry. 1997;272:8459–8465. doi: 10.1074/jbc.272.13.8459. [DOI] [PubMed] [Google Scholar]
  82. Yim N, Ryu SW, Choi K, Lee KR, Lee S, Choi H, Kim J, Shaker MR, Sun W, Park JH, Kim D, Heo WD, Choi C. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nature Communications. 2016;7:12277. doi: 10.1038/ncomms12277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Zacharias DA, Violin JD, Newton AC, Tsien RY. Partitioning of lipid-modified monomeric gfps into membrane microdomains of live cells. Science. 2002;296:913–916. doi: 10.1126/science.1068539. [DOI] [PubMed] [Google Scholar]
  84. Zhang M, Schekman R. Cell biology unconventional secretion, unconventional solutions. Science. 2013;340:559–561. doi: 10.1126/science.1234740. [DOI] [PubMed] [Google Scholar]
  85. Zhang YQ, Chandra SS. Oligomerization of cysteine string protein alpha mutants causing adult neuronal ceroid lipofuscinosis. Biochimica et Biophysica Acta. 2014;1842:2136–2146. doi: 10.1016/j.bbadis.2014.07.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Zhang M, Liu L, Lin X, Wang Y, Li Y, Guo Q, Li S, Sun Y, Tao X, Zhang D, Lv X, Zheng L, Ge L. A translocation pathway for vesicle-mediated unconventional protein secretion. Cell. 2020;181:637–652. doi: 10.1016/j.cell.2020.03.031. [DOI] [PubMed] [Google Scholar]
  87. Zinsmaier KE. Cysteine-String protein’s neuroprotective role. Journal of Neurogenetics. 2010;24:120–132. doi: 10.3109/01677063.2010.489625. [DOI] [PubMed] [Google Scholar]

Editor's evaluation

Suzanne R Pfeffer 1

This study describes a comprehensive set of classical techniques in biochemistry and cell biology characterizing the unconventional secretory mechanism of α-synuclein, an important contributor to neurodegeneration. The major finding is that palmitoylated DNAJC5 oligomers play a central role in this unusual secretory pathway, presumably by mediating entry of α-synuclein into late endosomes. Future work will clarify the mechanisms by which this cargo is exported from the cell.

Decision letter

Editor: Suzanne R Pfeffer1

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Decision letter after peer review:

[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]

Thank you for submitting the paper "Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Senior Editor. The reviewers have opted to remain anonymous.

Comments to the Authors:

We are sorry to say that the reviewers agreed that too much additional information would be needed to continue consideration of the present manuscript version. However, we would welcome a new submission that can address the most substantive issues raised by the reviewers as described below. The reviewers also asked me to highlight a concern related to the potential impact of the story in terms of the limitations of over-expression in a single cell line that may not be relevant to synucleinopathies (versus neurons, for instance).

Reviewer #1 (Recommendations for the authors):

In this paper, the precise role of DNAJC5 in unconventional secretion of α-synuclein was studied. Elucidating the molecular mechanism of this process is not only an interesting question in basic research but is also of high relevance with regard to potential biomedical applications in the context of neurodegenerative disorders. The current state of the literature is quite heterogenous with a number of distinct pathways being proposed to play a role in α-synuclein secretion, including a potential role for exosomes and cell-connecting nanotubes, among others.

Here, the authors aimed at reconstituting α-synuclein secretion in a general human cell line, HEK293T cells. A particular focus was given to DNAJC5, a protein that has previously been demonstrated to play a role in this process. In addition, palmitoylation was already known to mediate membrane attachment of DNAJC5. The authors demonstrate that both palmitoylated and non-palmitoylated DNAJC5 are secreted alongside α-synuclein. However, while palmitoylated DNAJC5 was found associated with some kind of extracellular vesicles, non-palmitoylated DNAJC5 and monomeric α-synuclein were found as soluble proteins in cellular supernatants. The authors further show that palmitoylation of DNAJC5 is required for α-synuclein secretion.

Using imaging techniques, the authors found DNAJC5 and α-synuclein to be associated with a population of endosomes. Along with cell fractionation and protease-protection experiments, these experiments were interpreted in a way that both proteins are located in the lumen of endosomes. They were further taken as evidence that DNAJC5 mediates translocation of α-synuclein from the cytoplasm into the lumen of endosomes.

In a further set of experiments, the authors aimed at addressing the folding state of α-synuclein while it is transported into the extracellular space. Using an elegant experimental system, evidence was provided that α-synuclein remains folded during all steps of its transport route.

Finally, the authors provide evidence for DNAJC5 to oligomerize, a process that is enhanced when the J domain is deleted. They also find that the J domain is not required for α-synuclein secretion.

As a bottom line the authors suggest that palmitoylated species of DNAJC5 oligomers form or link to other components of a pore in late endosomes through which α-synuclein translocates into their lumen. This potential step of α-synuclein membrane translocation is proposed to be the critical process that targets α-synuclein into the extracellular space.

In general, I appreciate this study that uses classical methods in biochemistry and cell biology collecting a number of important insights about the unconventional secretory pathway of α-synuclein.

In the following, I would like to point out a number of questions and suggestions the authors may want to address to improve this manuscript:

– Why and how do cells secrete non-palmitoylated DNAJC5, a variant that cannot associate with membranes? And why does palmitoylated DNAJC5 end up on extracellular vesicles, a species that is proposed to be inserted as an oligomer into the limiting membrane of late endosomes? When late endosomes fuse with the plasma membrane as suggested by the authors, palmitoylated DNAJC5 should remain in the inner leaflet of the plasma membrane. Based on the mechanism of α-synuclein secretion proposed in this study, both of these phenomena are difficult to incorporate into the concept of the authors.

– I am not sure whether the imaging experiments shown in Figure 4 and its supplements unequivocally demonstrate a luminal localization of the proteins in question. I also find the protease protection experiments to be limited in their conclusiveness since only a minor fraction of α-synuclein and DNAJC5 appear to be protected. Is there a way to produce further independent evidence for these claims? Finally, the time-lapse video provided as a supplement does not convince me with regard to the suggested role of DNAJC5 promoting membrane translocation of α-synuclein.

– To me it seems unclear whether the populations of α-synuclein and DNAJC5 found on endosomes are necessarily linked to the unconventional secretory mechanism of α-synuclein. Isn't it also possible that this material is derived from endocytosis of α-synuclein and DNAJC5? In particular with regard to the populations that are potentially in the lumen of these endosomes?

– The experimental evidence for DNAJC5 oligomers mediating membrane translocation of α-synuclein remains limited. I think this paper could contribute a major advance to the field if the observed oligomers could be characterized in more detail as has been done in other studies in the field. For example, beyond the observation of SDS-resistant oligomers in gels, FCS techniques could be used to precisely determine the oligomeric state of DNAJC5 in a native state. In addition. there are biophysical assays that allow to observe pore formation with purified proteins and artificial membrane vesicles. If there is a pore, its cut-off size could be determined and compared to the dimensions of α-synuclein. The authors indicate in the discussion that DNAJC5 might not be able to form a pore itself and that this process might be coupled to CD98. I think these aspects remain vague, however, insights into these questions would make up a true advance in the field.

– While the technique used to study the folding state of α-synuclein during its transport into the extracellular space is very elegant, in my opinion a positive control is missing, i.e. an unconventionally secreted protein whose secretion depends on an intermediate state that is unfolded. I think Interleukin 1β could serve as such a control.

Reviewer #2 (Recommendations for the authors):

In this manuscript, Wu et al. investigate the mechanisms through which the co-chaperone DNAJC5 regulates unconventional secretion of α-synuclein. The authors have some interesting findings such as palmitoylation is important for this process, but whether DNAJC5 itself was necessary is unclear. Addressing this ambiguity could lead to meaningful insights and the study could provide a cell biological basis for α-synuclein spread in Parkinson's disease.

Several additional experiments and quantification of the data presented will greatly enhance the quality of this manuscript.

Figure 1-NP-DNAJC5 and P-DNAJC5. The palmitoylation status of P-DNAJC5 should be confirmed by treating with hydroxylamine and checking if the protein now runs at NP-DNAJC5.

Figure 1-Please rule out that expression of the various constructs is not causing cell death.

Figure 1-S1-Can the authors comment on why DNAJC5 levels in the medium is decreased when PD mutants of α-synuclein are expressed? It would be helpful to quantitate these data to see the impact of PD mutations.

Figure 1-S2-Quercetin is rather non-specific and toxic. The data would be bolstered if in Figure S2E, the luciferase data is accompanied by western blots for α-synuclein and DNAJC5 (in addition to tubulin).

Figure 1-S2F-G- The effect of the KD should be quantified. KD of DNJAC5 does not seem to impact α-synuclein secretion. Is the effect on α-synuclein secretion even significant? These data with Figure 3 would argue that DNAJC5 itself is not necessary for secretion of α-synuclein. In this regard, can you substitute DNAJC5 with any heavily palmitoylated protein?

Figure 1-S2F-G- These data suggest that PATs that palmitoylate DNAJC may be important for secretion of α-synuclein. Also, KD of HIP14 would be instructive.

Figure 3-the ratio of DNAJC5-NP/P for the various conditions should be quantified.

Figure 3-The L115R mutant is retained in the Golgi. Does treatment with 2-BA also result in retention of DNAJC5 in the Golgi? If so, how does this fit into the model proposed for α-synuclein secretion.

Figure 4-How many large endosomes contain both DNAJC5 and α-synuclein? This is important to ascertain as it is not evident from the images shown that the miniscule amount of α-synuclein in endosomes accounts for amounts seen by western blotting of media. Also, why is the α-synuclein within the endosome not diffuse (as would be expected from a monomer) but rather punctate?

Figure 4-mNeo-Green tagging in the N-terminus of α-synuclein will prevent the protein from folding properly.

Lastly recapitulating these data in neurons would increase the significance of these findings.

Discussion is very speculative.

Reviewer #3 (Recommendations for the authors):

The authors describe a mechanism by which DNAJC5 stimulates the extracellular secretion of α-synuclein in a manner dependent on the palmitoylation of DNAJC5 which serves to anchor the protein to the membrane. There may be an additional role for oligomerization of DNAJC5 in facilitating α-syn secretion, as modifications to the protein which induce oligomerization appear to rescue deficits observed in palmitoyl-deficient mutants. The authors propose that the secretion of α-synuclein proceeds through an intermediate step of localization into late endosomal compartments, which appears to be disrupted in DNAJC5 mutants. Broadly this paper uses a combination of cellular fractionation, immunoblot and immunofluorescence microscopy in HEK 293 cells overexpressing a range of DNAJC5 constructs to dissect the role of this protein in α-synuclein export.

Advance over previous work:

The observation that DNAJC5 can mediate extracellular secretion of aSyn was previously described (Fontaine et al., 2016). Similarly, the importance of palmitoylation of DNAJC5 has been extensively studied (for instance Greaves et al. 2006 and 2012). Thus, it is perhaps not altogether surprising that DNAJC5 palmitoylation is important for its facilitatory effect on aSyn secretion.

Importance:

The mechanism described in this work appears to mediate the secretion of monomeric, but not aggregated forms (beyond artificially fused tandem repeats of aSyn dimers and tetramers) of synuclein. There is a well-established role for cell-cell transmission of misfolded aSyn oligomers and fibrils in synucleinopathies, which the authors briefly describe in the introduction. However, the role of aSyn monomer secretion in disease (or physiological function) is much less clear. From the context of understanding and treating synucleinopathies, the importance of the findings in this manuscript as currently written are thus somewhat unclear.

Similarly, it would be important to know how generalizable the effects of palmitoylation are on the secretion of other proteins involved in neurodegenerative diseases such as Tau and TDP43, which like aSyn, were previously shown to be dependent on DNAJC5 (Fontaine et al., 2016).

Finally, in this work the authors primarily use a combination of western blot, differential centrifugation, imaging and the introduction of specific mutations to analyze biochemical features of DNAJC5 that contribute to aSyn secretion. While the methods are appropriate, there are limitations to the experimental design (limited technical and biological replication) and choice of model system (predominantly overexpression in a single cellular model) that limit the interpretation of the data presented.

1. A limitation of this work is that the findings appear largely to be drawn from overexpression systems in a single cell line. Only in Figure 1 -Supplement 2 do the authors attempt to determine whether the role of DNAJC5 in regulating synuclein export is conserved under endogenous expression levels, however unfortunately these data are not very convincing. The effect of DNAJC5 knockdown in particular does not appear to support a significant role of the endogenous DNAJC5 protein in α-Syn export (although there may be an effect, the experiment is likely underpowered and no statistically significant effect was reported). The data stemming from the use of quercitin are also difficult to interpret as this natural product has been reported to have multiple targets, especially when used at high doses (the authors here have used it in the micro-molar range). Additional demonstration that DNAJC5 plays a role in α-synuclein export under endogenous expression conditions and in more relevant cellular models would greatly aid the argument that the mechanisms the authors have uncovered are part of a physiologically or disease-relevant pathway.

2. An important limitation of this manuscript is the lack of information regarding replicability of the observations. In many figures only a single western blot showing 1 or 2 replicates are shown. No information is given about whether the replicates that are shown are biological or technical replicates, and no information is given about whether additional experiments were performed (i.e. if these are meant to be representative images or if this represents the sum-total of the data). In figures where quantification has been performed (e.g. Figure 1 supplement 2) error bars are shown with no indication of what they represent (SD versus SEM) or any indication of how many replicates were performed. Similarly, with most immunofluorescence panels only a single image of a single cell is shown, from which the reader is expected to draw conclusions. Showing sufficient replication of the findings (perhaps through quantification performed on the blots and images) would help argue that these data are in fact robust and reproducible. Relatedly, the authors assertion that α-synuclein internalization into endosomes requires a functional DNAJC5 seems to be based largely on visual inspection of a small number of endosomes in single cells. Even among the small number of vesicles shown, it is clear that the amount of α-syn present in vesicles is highly variable, even within a single cell. Therefore, additional (and ideally more quantitative) evidence is required to support the conclusion that endosomal localization requires DNAJC5. In light of these apparent limitations pertaining to both technical and biological replication of some key findings across independent experiments, the data presented are somewhat unconvincing.

Other comments:

Most immunofluorescence figures are inadequately labelled. It is often unclear which images come from which cell lines. It is also recommended to use a color-blind friendly color scheme for all immunofluorescence images.

A methods section for Western blots is absent. This should include the antibodies used and at what dilution. In addition, the antibodies used should be denoted in the Figures or Figure legends for all Western blot panels.

Detailed section-by-section comments:

Introduction

– Several statements in the intro that describe previous findings related to aSyn export or the existence of extracellular aSyn would benefit from specification of the specific state of aSyn that is being referenced (i.e. are the authors speaking about monomeric, fibrillar or other forms of aSyn?)

– Sentence ending on line 65 should have a citation

– In the sentence ending on line 67 the authors refer to "unconventional traffic" but do not provide enough context for the reader to understand what is meant by "unconventional" (i.e. it might help to define conventional and unconventional)

– Line 65 – in previous works showing release of aSyn is mediated by DNAJC5, what form of aSyn was studied?

– Line 71 – please specify under what condition DNAJC5 was found to be neuroprotective.

– In the paragraph starting on line 42 the authors introduce the concept of pathological aSyn spreading and imply a potential role for extracellular secretion, however they later state that DNAJC5 (a protein the reader is then told is involved in this secretion) plays a neuroprotective role (line 71 and 72). Do the authors consider this to be a discrepancy in if so what might explain it? (perhaps a topic to address in the discussion)

Results

– In Figure 1, only secretion of overexpressed aSyn is studied. It might be important to show a role for this pathway in secretion of aSyn at physiological expression levels.

– Line 121: The effect of siRNA knockdown is marginal, and likely statistically insignificant and does not support the authors statements

– Line 150: this statement would be better supported if the authors had a positive control showing that aSyn oligomers can co-ip under the specific conditions used in this experiment (for example can oligomers be co-ip'ed from the cell lysate?)

– Quercitin has been reported to have multiple targets, especially at high doses. Furthermore, the dose of quercitin required to elicit a response in the paper cited by the authors to support the use of this drug is considerably higher than that used by the authors here. Potential off-target effects of the drug should be acknowledged as a limitation.

– In Figure 3 Supplement 1B the relative amount of aSyn to tubulin in cell lysate is not a clear trend. In this figure quantification of the ratio between aSyn and tubulin would assist in interpretation.

Figure 3 D and E – this and other panels showing aSyn in media would benefit from the inclusion of a loading control for EVs ◊ this might help clarify whether a global increase in secretion of EVs might contribute to the increase in aSyn and DNAJC5 observed in media.

– Figure 3 B and C – it appears that although there is a decrease in aSyn secretion following 2-BA treatment, there is no corresponding reduction in cytosolic aSyn. What could explain this discrepancy? Here again, quantifications might assist in uncovering whether small effects are present that are not obvious by visual inspection alone.

– Figure 4 – It appears here that data is shown only either for L115R mutant or WT when in fact these should both be shown side by side.

– In Figure 4 the labelling of which images come from which genetic backgrounds is somewhat unclear. For example, Panel A seems to show staining from cells expressing a wild type DNAJC5 whereas panel B seems to show the L115R mutant, however this is not clearly denoted in the figure or figure legend. It would be helpful if the images corresponding to direct comparisons of the same staining from either WT or mutant were shown side by side in the same figure.

– Figure 4: The conclusion that aSyn internalization into endosomes requires functional DNAJC5 appears to be based only on visual inspection of the 3 representative endosomes shown in panels B and C, which are derived from each from a single cell. In addition, the fractionation experiment is shown only for WT DNAJC5, and not L115R. To reach this conclusion the authors should provide more robust data supporting a difference in endosomal localization of synuclein. This could be achieved by quantifying the aSyn signal in endosomes from a larger number of endosomes, and importantly, from multiple cells derived from distinct biological replicates.

– Figure 4: Confirming the localization of DNAJC5 and aSyn ultrastructurally, for instance by immuno-EM or CLEM would help further support the authors' interpretation regarding localization and topology.

– Figure 4 supplementary video is not referred to at all in the text pertaining to Figure 4, only much later in the discussion.

– Figure 5: It appears that GFP was used as a transfection control in these experiments. In previous Western blot figures no transfection control was indicated. If one was used it should be specified.

– Line 211 should use Greek character for α

– Figure 5 Panel E+F The authors indicate that the asterisk marks a non-specific band, however this does not explain why a non-specific band would appear in only the conditions transfected with the thermostable aSyn mutants. Further, when you compare panels E and F, the location of the non-specific band appears to change relative to aSyn. Interpretation of these western blots would be assisted if molecular weight markers were shown alongside the blots.

– Figure 6: Definition of the abbreviations (PNS, M and C) used in the figure should be provided

– As stated for previous figures, the presence of aSyn in endosomal compartments could more effectively be shown with quantification across multiple replicates

– Figure 7D and Line 311. The blot presented does not provide strong justification for the statement that deletion of the J domain does not affect aSyn secretion. It seems like some mutants may in fact stimulate greater aSyn secretion compared to WT, but it is difficult to draw any conclusion from visual inspection of this blot alone.

eLife. 2023 Jan 10;12:e85837. doi: 10.7554/eLife.85837.sa2

Author response


Reviewer #1 (Recommendations for the authors):

In this paper, the precise role of DNAJC5 in unconventional secretion of α-synuclein was studied. Elucidating the molecular mechanism of this process is not only an interesting question in basic research but is also of high relevance with regard to potential biomedical applications in the context of neurodegenerative disorders. The current state of the literature is quite heterogenous with a number of distinct pathways being proposed to play a role in α-synuclein secretion, including a potential role for exosomes and cell-connecting nanotubes, among others.

Here, the authors aimed at reconstituting α-synuclein secretion in a general human cell line, HEK293T cells. A particular focus was given to DNAJC5, a protein that has previously been demonstrated to play a role in this process. In addition, palmitoylation was already known to mediate membrane attachment of DNAJC5. The authors demonstrate that both palmitoylated and non-palmitoylated DNAJC5 are secreted alongside α-synuclein. However, while palmitoylated DNAJC5 was found associated with some kind of extracellular vesicles, non-palmitoylated DNAJC5 and monomeric α-synuclein were found as soluble proteins in cellular supernatants. The authors further show that palmitoylation of DNAJC5 is required for α-synuclein secretion.

Using imaging techniques, the authors found DNAJC5 and α-synuclein to be associated with a population of endosomes. Along with cell fractionation and protease-protection experiments, these experiments were interpreted in a way that both proteins are located in the lumen of endosomes. They were further taken as evidence that DNAJC5 mediates translocation of α-synuclein from the cytoplasm into the lumen of endosomes.

In a further set of experiments, the authors aimed at addressing the folding state of α-synuclein while it is transported into the extracellular space. Using an elegant experimental system, evidence was provided that α-synuclein remains folded during all steps of its transport route.

Finally, the authors provide evidence for DNAJC5 to oligomerize, a process that is enhanced when the J domain is deleted. They also find that the J domain is not required for α-synuclein secretion.

As a bottom line the authors suggest that palmitoylated species of DNAJC5 oligomers form or link to other components of a pore in late endosomes through which α-synuclein translocates into their lumen. This potential step of α-synuclein membrane translocation is proposed to be the critical process that targets α-synuclein into the extracellular space.

In general, I appreciate this study that uses classical methods in biochemistry and cell biology collecting a number of important insights about the unconventional secretory pathway of α-synuclein.

In the following, I would like to point out a number of questions and suggestions the authors may want to address to improve this manuscript:

– Why and how do cells secrete non-palmitoylated DNAJC5, a variant that cannot associate with membranes? And why does palmitoylated DNAJC5 end up on extracellular vesicles, a species that is proposed to be inserted as an oligomer into the limiting membrane of late endosomes? When late endosomes fuse with the plasma membrane as suggested by the authors, palmitoylated DNAJC5 should remain in the inner leaflet of the plasma membrane. Based on the mechanism of α-synuclein secretion proposed in this study, both of these phenomena are difficult to incorporate into the concept of the authors.

The secretion of DNAJC5 in extracellular vesicles has been reported before. In our new data, we also found that endogenous DNAJC5 in differentiated neuroblastoma SH-SY5Y cells was packaged into exosomes, demonstrated both by protease protection assay and sucrose gradient flotation (Figure 7 —figure supplement 1). We think the palmitoylated DNAJC5 (P-DNAJC5) is inserted on the cytosolic side of late endosomes, and then is packaged inside the intraluminal vesicles by membrane invagination, like many other exosome markers, e.g. CD63.

We also were curious about the secretion of non-palmitoylated DNAJC5 (NP-DNAJC5) in HEK293T cells. As the reviewer pointed out, NP- DNAJC5 does not associate with membrane. We noticed that one distinct characteristic of palmitoylation among other protein lipidation is its reversible nature. We have tested if NP-DNAJC5 is generated from depalmitoylation of packaged P-DNAJC5 in late endosomes by knocking out palmitoyl-protein thioesterase 1 (PPT1) in HEK293T cells by CRISPR/Cas9 (Author response image 1). PPT1 has been reported to catalyze the deplamitoylation of P-DNAJC5 in vitro and its deficiency also causes neurodegenerative disorder. However, we did not observe a decrease of secreted NP-DNAJC5 in PPT1 KO cells (Author response image 1). Given several other identified depalmitoylation thioesterases, we think there could be redundant enzymes responsible for the depalmitoylation of DNAJC5. Note we found less NP-DNAJC5 in SH-SY5Y cells (Figure 7A) and expression of a non-reversible XP-DNAJC5 also induced a-syn secretion (Figure 6). Thus we think the P-DNAJC5 is more important for this unconventional secretion pathway and the secretion of NPDNAJC5 may be result from the action of an unknown thioesterase in HEK293T cells.

Author response image 1.

Author response image 1.

– I am not sure whether the imaging experiments shown in Figure 4 and its supplements unequivocally demonstrate a luminal localization of the proteins in question. I also find the protease protection experiments to be limited in their conclusiveness since only a minor fraction of α-synuclein and DNAJC5 appear to be protected. Is there a way to produce further independent evidence for these claims? Finally, the time-lapse video provided as a supplement does not convince me with regard to the suggested role of DNAJC5 promoting membrane translocation of α-synuclein.

We performed quantification analysis on the percentage of luminal a-syn with or without DNAJC5. We now report a statistically significant difference of ratio of luminal localized a-syn (Figure 4H).

We acknowledge that the percentage of protected a-syn is low. Given that a-syn is known to bind membrane peripherally, it is not too surprising that much a-syn tethers outside of membrane. We have performed an independent nanoluciferase (Nluc) quenching assay developed by other members in our lab, the principle of which is reported in another manuscript (Williams et al., 2022). Again, the protection efficiency is low (less than 10%) (Author response image 2, left). As a control, cytosolic Nluc-a-syn was not protected. A lithium chloride wash to reduce peripherally associated a-syn increased the protected percentage to ~25% (Author response image 2, right).

Author response image 2.

Author response image 2.

– To me it seems unclear whether the populations of α-synuclein and DNAJC5 found on endosomes are necessarily linked to the unconventional secretory mechanism of α-synuclein. Isn't it also possible that this material is derived from endocytosis of α-synuclein and DNAJC5? In particular with regard to the populations that are potentially in the lumen of these endosomes?

The visualization of proteins in the lumen of enlarged multivesicular bodies (MVBs) was widely used to indicate protein packaged into exosomes. We repeated the experiments by treating the cells with 80 μm dynasore to inhibit endocytosis. A-syn and DNAJC5 are still found in the lumen of the endosomes (Author response image 3).

Author response image 3.

Author response image 3.

– The experimental evidence for DNAJC5 oligomers mediating membrane translocation of α-synuclein remains limited. I think this paper could contribute a major advance to the field if the observed oligomers could be characterized in more detail as has been done in other studies in the field. For example, beyond the observation of SDS-resistant oligomers in gels, FCS techniques could be used to precisely determine the oligomeric state of DNAJC5 in a native state. In addition. there are biophysical assays that allow to observe pore formation with purified proteins and artificial membrane vesicles. If there is a pore, its cut-off size could be determined and compared to the dimensions of α-synuclein. The authors indicate in the discussion that DNAJC5 might not be able to form a pore itself and that this process might be coupled to CD98. I think these aspects remain vague, however, insights into these questions would make up a true advance in the field.

We agree that the insights into the oligomerization of DNAJC5 and identification of other components in the translocation machineries will be the important next step in our research. However, we don’t have access to FCS in the lab and the biophysical analysis of in vitro reconstituted DNAJC5 oligomers is challenging. Our gel filtration results showed that DNAJC5 formed oligomers in a non-denaturing environment (without SDS). Currently, we are working on identification of DNAJC5 interacting proteins for a-syn translocation. This will be covered in our future work.

– While the technique used to study the folding state of α-synuclein during its transport into the extracellular space is very elegant, in my opinion a positive control is missing, i.e. an unconventionally secreted protein whose secretion depends on an intermediate state that is unfolded. I think Interleukin 1β could serve as such a control.

We thank the reviewer to suggest this critical control. After we consulted with the authors of Interleukin 1b (IL1b) secretion, they raised the concern that 3H bundle may alter the membrane localization of IL1b based on its sequence. Instead, we turned to the mitochondrial protein import pathway, which is also dependent on protein-unfolding. This control has been added as a supplementary figure where the incorporation of 3H after the transit peptide blocked import of a mitochondrial matrix reporter protein (Figure 5 —figure supplement 2).

Reviewer #2 (Recommendations for the authors):

In this manuscript, Wu et al. investigate the mechanisms through which the co-chaperone DNAJC5 regulates unconventional secretion of α-synuclein. The authors have some interesting findings such as palmitoylation is important for this process, but whether DNAJC5 itself was necessary is unclear. Addressing this ambiguity could lead to meaningful insights and the study could provide a cell biological basis for α-synuclein spread in Parkinson's disease.

Several additional experiments and quantification of the data presented will greatly enhance the quality of this manuscript.

Figure 1-NP-DNAJC5 and P-DNAJC5. The palmitoylation status of P-DNAJC5 should be confirmed by treating with hydroxylamine and checking if the protein now runs at NP-DNAJC5.

The hydroxylamine experiment was performed and added as a supplementary figure (Figure 1—figure supplement 1).

Figure 1-Please rule out that expression of the various constructs is not causing cell death.

The cell viability assay was performed and added as a supplementary figure (Figure 1—figure supplement 2A).

Figure 1-S1-Can the authors comment on why DNAJC5 levels in the medium is decreased when PD mutants of α-synuclein are expressed? It would be helpful to quantitate these data to see the impact of PD mutations.

This quantification was performed and is labeled in the figures. The a-syn PD mutants are known to affect its aggregation propensity. It is possible that the DNAJC5 co-aggregates with a-syn PD mutants so that less DNAJC5 is secreted. Further experiments would need to be performed to address such a hypothesis but that is beyond the scope of the current manuscript.

Figure 1-S2-Quercetin is rather non-specific and toxic. The data would be bolstered if in Figure S2E, the luciferase data is accompanied by western blots for α-synuclein and DNAJC5 (in addition to tubulin).

The immunoblots of a-syn and DNAJC5 were added in a supplementary figure (Figure 1—figure supplement 3E).

Figure 1-S2F-G- The effect of the KD should be quantified. KD of DNJAC5 does not seem to impact α-synuclein secretion. Is the effect on α-synuclein secretion even significant? These data with Figure 3 would argue that DNAJC5 itself is not necessary for secretion of α-synuclein. In this regard, can you substitute DNAJC5 with any heavily palmitoylated protein?

We generated a DNAJC5 CRISPR/Cas9 KO HEK293T cell line and repeated the experiment. The effect of DNAJC5 is more significant with the treatment of BaFA1. We have updated the supplementary figure with the KO results accordingly.

Figure 1-S2F-G- These data suggest that PATs that palmitoylate DNAJC may be important for secretion of α-synuclein. Also, KD of HIP14 would be instructive.

We tried to generate CRIPSR/Cas9 HIP14 KO HEK293T cells. Unfortunately, we could not find a good antibody against HIP14 in HEK293T cells but we found decreased P-DNAJC5 in several clones. Accordingly, the level of extracellular a-syn decreased about 40%.

Author response image 4.

Author response image 4.

Figure 3-the ratio of DNAJC5-NP/P for the various conditions should be quantified.

The ratio has been quantified and added as a new Panel to the Figure 3 (Figure 3B).

Figure 3-The L115R mutant is retained in the Golgi. Does treatment with 2-BA also result in retention of DNAJC5 in the Golgi? If so, how does this fit into the model proposed for α-synuclein secretion.

We confirmed Golgi retention of the L115R mutant protein by immunofluorescence (IF). As suggested by the reviewer, 2-BA treatment also resulted in Golgi retention of DNAJC5. Based on the observation above, we think that mislocalized NP-DNAJC5 failed to insert into the membrane of late endosomes, thus as for soluble DNAJC5 in the cytosol, was unable to mediate a-syn secretion. The Golgi retention results are summarized in Figure 3 —figure supplement 3.

Figure 4-How many large endosomes contain both DNAJC5 and α-synuclein? This is important to ascertain as it is not evident from the images shown that the miniscule amount of α-synuclein in endosomes accounts for amounts seen by western blotting of media. Also, why is the α-synuclein within the endosome not diffuse (as would be expected from a monomer) but rather punctate?

We quantified the DNAJC5 and a-synuclein containing endosomes and the difference between the absence and presence of DNAJC5 is significant (Figure 4H). The miniscule amount of internalized asynuclein is contributed by the high background of cytosolic a-syn.

In respect to the punctate distribution of internalized a-syn, we think that it is possible that soluble asyn may tether on the membrane of intraluminal vesicles. The stickiness of a-syn may contribute to membrane-association inside the lumen of endosomes.

Figure 4-mNeo-Green tagging in the N-terminus of α-synuclein will prevent the protein from folding properly.

As we demonstrate in Figure 5, DNAJC5-mediated a-syn secretion is independent of protein unfolding. The secretion of N-terminally tagged a-syn is confirmed as normal (Author response image 5). We also generated an a-syn construct with C-terminally tagged mNeon-Green (a-syn-mNG). The internalization of C-tagged a-syn-mNG was also confirmed by live cell imaging (Author response image 5).

Author response image 5.

Author response image 5.

Lastly recapitulating these data in neurons would increase the significance of these findings.

We have recapitulated several key data in RA treated differentiated neuroblastoma (SH-SY5Y) cells, in human patient-derived iPSC differentiated dopaminergic neurons and in mouse mESCdifferentiated dopaminergic neurons. All these new data are summarized in an updated Figure 7.

Discussion is very speculative.

We have updated Discussion section based on our new data.

Reviewer #3 (Recommendations for the authors):

The authors describe a mechanism by which DNAJC5 stimulates the extracellular secretion of α-synuclein in a manner dependent on the palmitoylation of DNAJC5 which serves to anchor the protein to the membrane. There may be an additional role for oligomerization of DNAJC5 in facilitating α-syn secretion, as modifications to the protein which induce oligomerization appear to rescue deficits observed in palmitoyl-deficient mutants. The authors propose that the secretion of α-synuclein proceeds through an intermediate step of localization into late endosomal compartments, which appears to be disrupted in DNAJC5 mutants. Broadly this paper uses a combination of cellular fractionation, immunoblot and immunofluorescence microscopy in HEK 293 cells overexpressing a range of DNAJC5 constructs to dissect the role of this protein in α-synuclein export.

Advance over previous work:

The observation that DNAJC5 can mediate extracellular secretion of aSyn was previously described (Fontaine et al., 2016). Similarly, the importance of palmitoylation of DNAJC5 has been extensively studied (for instance Greaves et al. 2006 and 2012). Thus, it is perhaps not altogether surprising that DNAJC5 palmitoylation is important for its facilitatory effect on aSyn secretion.

Importance:

The mechanism described in this work appears to mediate the secretion of monomeric, but not aggregated forms (beyond artificially fused tandem repeats of aSyn dimers and tetramers) of synuclein. There is a well-established role for cell-cell transmission of misfolded aSyn oligomers and fibrils in synucleinopathies, which the authors briefly describe in the introduction. However, the role of aSyn monomer secretion in disease (or physiological function) is much less clear. From the context of understanding and treating synucleinopathies, the importance of the findings in this manuscript as currently written are thus somewhat unclear.

We consistently see the majority of extracellular a-syn secreted is soluble, both in HEK293T cells and in neuronal cells. Previous publications also reported that increased extracellular a-syn in patient-derived neuronal culture medium is soluble and not associated with exosomes (Fernandes et al., Stem Cell Reports, 2016). The release of soluble a-syn can be a protective mechanism to alleviate the intracellular a-syn pathology before the onset of synucleinopathies. We revised the discussion to clarify the relevance of our findings.

Similarly, it would be important to know how generalizable the effects of palmitoylation are on the secretion of other proteins involved in neurodegenerative diseases such as Tau and TDP43, which like aSyn, were previously shown to be dependent on DNAJC5 (Fontaine et al., 2016).

We focus on the mechanism of a-syn secretion in this manuscript but a visiting scholar in our lab has been working on DNAJC5 regulated Tau secretion and confirmed some of our findings in Tau secretion. This will be covered in their research.

Finally, in this work the authors primarily use a combination of western blot, differential centrifugation, imaging and the introduction of specific mutations to analyze biochemical features of DNAJC5 that contribute to aSyn secretion. While the methods are appropriate, there are limitations to the experimental design (limited technical and biological replication) and choice of model system (predominantly overexpression in a single cellular model) that limit the interpretation of the data presented.

We have quantified our imaging and blots, and recapitulated our findings in several neuronal cell culture lines at endogenous level.

1. A limitation of this work is that the findings appear largely to be drawn from overexpression systems in a single cell line. Only in Figure 1 -Supplement 2 do the authors attempt to determine whether the role of DNAJC5 in regulating synuclein export is conserved under endogenous expression levels, however unfortunately these data are not very convincing. The effect of DNAJC5 knockdown in particular does not appear to support a significant role of the endogenous DNAJC5 protein in α-Syn export (although there may be an effect, the experiment is likely underpowered and no statistically significant effect was reported). The data stemming from the use of quercitin are also difficult to interpret as this natural product has been reported to have multiple targets, especially when used at high doses (the authors here have used it in the micro-molar range). Additional demonstration that DNAJC5 plays a role in α-synuclein export under endogenous expression conditions and in more relevant cellular models would greatly aid the argument that the mechanisms the authors have uncovered are part of a physiologically or disease-relevant pathway.

We generated a CRISPR/Cas9 DNAJC5 KO HEK293T cells and repeated the experiment. The effect of DNAJC5 is more significant with the treatment of BaFA1. We have updated the supplementary figure with the KO results accordingly.

We have recapitulated several key data in differentiated neuroblastoma cells, human patient-derived iPSC differentiated dopaminergic neurons and mouse mESC differentiate dopaminergic neurons. Please see our updated Figure 7.

2. An important limitation of this manuscript is the lack of information regarding replicability of the observations. In many figures only a single western blot showing 1 or 2 replicates are shown. No information is given about whether the replicates that are shown are biological or technical replicates, and no information is given about whether additional experiments were performed (i.e. if these are meant to be representative images or if this represents the sum-total of the data). In figures where quantification has been performed (e.g. Figure 1 supplement 2) error bars are shown with no indication of what they represent (SD versus SEM) or any indication of how many replicates were performed. Similarly, with most immunofluorescence panels only a single image of a single cell is shown, from which the reader is expected to draw conclusions. Showing sufficient replication of the findings (perhaps through quantification performed on the blots and images) would help argue that these data are in fact robust and reproducible. Relatedly, the authors assertion that α-synuclein internalization into endosomes requires a functional DNAJC5 seems to be based largely on visual inspection of a small number of endosomes in single cells. Even among the small number of vesicles shown, it is clear that the amount of α-syn present in vesicles is highly variable, even within a single cell. Therefore, additional (and ideally more quantitative) evidence is required to support the conclusion that endosomal localization requires DNAJC5. In light of these apparent limitations pertaining to both technical and biological replication of some key findings across independent experiments, the data presented are somewhat unconvincing.

We have added the information when applicable in our figure legends and performed the quantification of endosomes.

Other comments:

Most immunofluorescence figures are inadequately labelled. It is often unclear which images come from which cell lines. It is also recommended to use a color-blind friendly color scheme for all immunofluorescence images.

We have added cell line information in the figure legends.

A methods section for Western blots is absent. This should include the antibodies used and at what dilution. In addition, the antibodies used should be denoted in the Figures or Figure legends for all Western blot panels.

We have added an immunoblot section in Methods. The antibodies used were listed in Key resource table. The dilution number was summarized in the method section.

Detailed section-by-section comments:

Introduction

– Several statements in the intro that describe previous findings related to aSyn export or the existence of extracellular aSyn would benefit from specification of the specific state of aSyn that is being referenced (i.e. are the authors speaking about monomeric, fibrillar or other forms of aSyn?)

We clarify the state of extracellular a-syn (monomers, oligomers and aggregates) in the Introduction.

– Sentence ending on line 65 should have a citation

The citation has been added (Fontaine et al., 2016).

– In the sentence ending on line 67 the authors refer to "unconventional traffic" but do not provide enough context for the reader to understand what is meant by "unconventional" (i.e. it might help to define conventional and unconventional)

The definition of “unconventional secretion” has been added.

– Line 65 – in previous works showing release of aSyn is mediated by DNAJC5, what form of aSyn was studied?

In Fontaine et al., 2016, the form of a-syn was not specified.

– Line 71 – please specify under what condition DNAJC5 was found to be neuroprotective.

Conventionally DNAJC5 is considered as a chaperone to prevent protein misfolding. Deletion and mutations in DNAJC5 cause neurodegeneration and premature death. The conditions were added in the text.

– In the paragraph starting on line 42 the authors introduce the concept of pathological aSyn spreading and imply a potential role for extracellular secretion, however they later state that DNAJC5 (a protein the reader is then told is involved in this secretion) plays a neuroprotective role (line 71 and 72). Do the authors consider this to be a discrepancy in if so what might explain it? (perhaps a topic to address in the discussion)

Calo et al., 2021 showed that DNAJC5 was able to reduce a-syn aggregates and increase monomeric a-syn. We also showed that the secreted a-syn mediated by DNAJC5 is mainly soluble with no stress conditions. In addition to its chaperone function, we hypothesized that DNAJC5 may play a positive role in helping to dispose of a-syn by secretion to prevent aggregation. We added a new paragraph in our discussion to address this.

Results

– In Figure 1, only secretion of overexpressed aSyn is studied. It might be important to show a role for this pathway in secretion of aSyn at physiological expression levels.

We studied secretion of endogenous a-syn in several neuronal cultures. In these neuronal cultures, DNAJC5 also plays a role in the secretion of soluble a-syn.

– Line 121: The effect of siRNA knockdown is marginal, and likely statistically insignificant and does not support the authors statements

We have generated a HEK293T DNAJC5 CRIPSR knockout (KO) cell line. BaFA1-stimulated a-syn secretion was decreased in DNAJC5 KO cell line.

– Line 150: this statement would be better supported if the authors had a positive control showing that aSyn oligomers can co-ip under the specific conditions used in this experiment (for example can oligomers be co-ip'ed from the cell lysate?)

The formation of a-syn oligomers is challenging in the cell culture conditions we used. When examined by gel filtration, almost all a-syn in cell lysate were soluble. Co-immunoprecipitation of oligomerized protein complexes has been widely used to detect the interaction between protomers.

– Quercitin has been reported to have multiple targets, especially at high doses. Furthermore, the dose of quercitin required to elicit a response in the paper cited by the authors to support the use of this drug is considerably higher than that used by the authors here. Potential off-target effects of the drug should be acknowledged as a limitation.

The titration experiment is used to optimize the concentration to inhibit DNAJC5 palmitoylation. Tubulin was used here only to monitor cell toxicity in the case of released tubulin in the medium, which was not observed in the experiment. We quantified the ratio of a-syn in media / a-syn in lysates to represent normalized a-syn secretion. The inhibition effect of DNAJC5 palmitoylation was quantified by the ratio between P-DNAJC5 and NP-DNAJC5 in the cell lysate.

We acknowledged the potential off-target effect of quercetin in the main text.

– In Figure 3 Supplement 1B the relative amount of aSyn to tubulin in cell lysate is not a clear trend. In this figure quantification of the ratio between aSyn and tubulin would assist in interpretation.

The titration experiment is used to optimize the concentration to inhibit DNAJC5 palmitoylation. Tubulin was used here only to monitor cell toxicity in the case of released tubulin in the medium, which was not observed in the experiment. We quantified the ratio of a-syn in media / a-syn in lysates to represent normalized a-syn secretion. The inhibition effect of DNAJC5 palmitoylation was quantified by the ratio between P-DNAJC5 and NP-DNAJC5 in the cell lysate.

Figure 3 D and E – this and other panels showing aSyn in media would benefit from the inclusion of a loading control for EVs ◊ this might help clarify whether a global increase in secretion of EVs might contribute to the increase in aSyn and DNAJC5 observed in media.

The detection of EV in this experiment is challenging, since all the secretion assays were performed with cell culture in 6-well plates. Detection of EV markers typically require large-scale culture.

– Figure 3 B and C – it appears that although there is a decrease in aSyn secretion following 2-BA treatment, there is no corresponding reduction in cytosolic aSyn. What could explain this discrepancy? Here again, quantifications might assist in uncovering whether small effects are present that are not obvious by visual inspection alone.

The population of secreted a-syn is only minor fraction of total a-syn in cell. We quantify the influence of a-syn secretion by both 2-BA treatment and L115R mutation.

In figure 4, we focus on the translocation of WT DNAJC5. The effect of L115R and rescue by XPL115R was shown in Figure 6.

– Figure 4 – It appears here that data is shown only either for L115R mutant or WT when in fact these should both be shown side by side.

In figure 4, we focus on the translocation of WT DNAJC5. The effect of L115R and rescue by XPL115R was shown in Figure 6.

– In Figure 4 the labelling of which images come from which genetic backgrounds is somewhat unclear. For example, Panel A seems to show staining from cells expressing a wild type DNAJC5 whereas panel B seems to show the L115R mutant, however this is not clearly denoted in the figure or figure legend. It would be helpful if the images corresponding to direct comparisons of the same staining from either WT or mutant were shown side by side in the same figure.

All the images shown in Figure 4 main figures are from DNAJC5 WT. Panel B show the localization of a-syn, not DNAJC5 L115R mutant. The names of each channel were labeled in images.

– Figure 4: The conclusion that aSyn internalization into endosomes requires functional DNAJC5 appears to be based only on visual inspection of the 3 representative endosomes shown in panels B and C, which are derived from each from a single cell. In addition, the fractionation experiment is shown only for WT DNAJC5, and not L115R. To reach this conclusion the authors should provide more robust data supporting a difference in endosomal localization of synuclein. This could be achieved by quantifying the aSyn signal in endosomes from a larger number of endosomes, and importantly, from multiple cells derived from distinct biological replicates.

We quantified the ratio of a-syn containing endosomes from multiple cells. A statistically significant difference was found between a-syn alone (Control) and a-syn co-transfected with DNAJC5 (Figure 4H).

– Figure 4: Confirming the localization of DNAJC5 and aSyn ultrastructurally, for instance by immuno-EM or CLEM would help further support the authors' interpretation regarding localization and topology.

The CLEM is challenging because most a-syn is soluble. Instead, a protease protection assay was performed to cross-validate our imaging data (Figure 4Fand4G).

– Figure 4 supplementary video is not referred to at all in the text pertaining to Figure 4, only much later in the discussion.

– Figure 5: It appears that GFP was used as a transfection control in these experiments. In previous Western blot figures no transfection control was indicated. If one was used it should be specified.

– Line 211 should use Greek character for α

– Figure 5 Panel E+F The authors indicate that the asterisk marks a non-specific band, however this does not explain why a non-specific band would appear in only the conditions transfected with the thermostable aSyn mutants. Further, when you compare panels E and F, the location of the non-specific band appears to change relative to aSyn. Interpretation of these western blots would be assisted if molecular weight markers were shown alongside the blots.

– Figure 6: Definition of the abbreviations (PNS, M and C) used in the figure should be provided

– As stated for previous figures, the presence of aSyn in endosomal compartments could more effectively be shown with quantification across multiple replicates

– Figure 7D and Line 311. The blot presented does not provide strong justification for the statement that deletion of the J domain does not affect aSyn secretion. It seems like some mutants may in fact stimulate greater aSyn secretion compared to WT, but it is difficult to draw any conclusion from visual inspection of this blot alone.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Figure 1—source data 1. Uncropped immunoblot and gel images corresponding to Figure 1.
    Figure 1—figure supplement 1—source data 1. Uncropped immunoblot images corresponding to Figure 1—figure supplement 1.
    Figure 1—figure supplement 2—source data 1. Uncropped immunoblot images corresponding to Figure 1—figure supplement 2.
    Figure 1—figure supplement 3—source data 1. Uncropped immunoblot images corresponding to Figure 1—figure supplement 3.
    Figure 2—source data 1. Uncropped immunoblot corresponding to Figure 2.
    Figure 2—figure supplement 1—source data 1. Uncropped immunoblot images corresponding to Figure 2—figure supplement 1.
    Figure 2—figure supplement 2—source data 1. Uncropped immunoblot images corresponding to Figure 2—figure supplement 2.
    Figure 2—figure supplement 3—source data 1. Uncropped gel images corresponding to Figure 2—figure supplement 3.
    Figure 3—source data 1. Uncropped immunoblot corresponding to Figure 3.
    Figure 3—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 3—figure supplement 1.
    Figure 3—figure supplement 2—source data 1. Uncropped immunoblot corresponding to Figure 3—figure supplement 2.
    Figure 4—source data 1. Uncropped immunoblot corresponding to Figure 4.
    Figure 5—source data 1. Uncropped immunoblot corresponding to Figure 5.
    Figure 5—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 5—figure supplement 1.
    Figure 5—figure supplement 2—source data 1. Uncropped immunoblot corresponding to Figure 5—figure supplement 2.
    Figure 6—source data 1. Uncropped immunoblot corresponding to Figure 6.
    Figure 6—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 6—figure supplement 1.
    Figure 7—source data 1. Uncropped immunoblot corresponding to Figure 7.
    Figure 7—figure supplement 1—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 1.
    Figure 7—figure supplement 2—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 2.
    Figure 7—figure supplement 3—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 3.
    Figure 7—figure supplement 4—source data 1. Uncropped immunoblot corresponding to Figure 7—figure supplement 4.
    Figure 8—source data 1. Uncropped immunoblot corresponding to Figure 8.
    MDAR checklist

    Data Availability Statement

    All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for all the Figures.


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES